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Encapsulation of islets in hydrogel microspheres (microgels) before 
transplantation into diabetic recipients can establish an adequate immuno-
isolation barrier to mitigate allogeneic rejection. The synthetic hydrogel macromer 
PEG-4MAL (4-arm polyethylene glycol terminated with maleimides) is an ideal 
candidate polymer for immunoisolation applications, since it can be easily 
modified with thiolated bioactive molecules, allowing precise control of islet 
microenvironment. Alginate microencapsulation dominates in literature even 
though alginate provides limited control of islet microenvironment, because no 
technique exists for islet encapsulation in synthetic microgels. Therefore, a 
microfluidic platform for the encapsulation of islets in size-controlled PEG-4MAL 
microgels was developed, and hydrogel composition was optimized to support 
encapsulated islet function. Islets microencapsulated in optimized PEG-4MAL 
restored glycemic control better than islets microencapsulated in alginate and 
equally as well as unencapsulated islets when delivered to epididymal fat pads in 
diabetic syngeneic mice within bulk vasculogenic hydrogels. Improved function 
was partially attributed to decreased microgel size vs. alginate, and therefore 




being investigated in allogeneic recipients. In a separate scheme, PEG-4MAL 
microgels were designed which could capture and display the chimeric 
immunomodulatory protein SA-FasL in its bioactive form. Simple 
cotransplantation of SA-FasL presenting microgels with unmodified allogeneic 
islets under the kidney capsule of diabetic mice resulted in long term graft 
acceptance without long term immunosuppression. Regulatory T cells mediated 
this acceptance since their ablation on day 50 post-transplantation prompted 
rapid graft rejection. Effective control or mitigation of immune responses is critical 
for successful outcomes in islet transplantation, and this work presents the 
development of two novel strategies for achieving long term function of 





CHAPTER 1: INTRODUCTION 
 
1.1 Type 1 Diabetes 
 Type 1 Diabetes (T1D) affects between 11-22 million people worldwide 
[1], and its incidence has been increasing at a rate of 3% per year [2, 3]. T1D is 
often referred to as juvenile diabetes because onset frequently occurs during 
childhood, and there was a dramatic 21% increase in prevalence from 2001-2009 
in US youths under 20 [4]. Annual healthcare costs associated with T1D exceed 
$14 billion dollars per year in the United States alone [5]. The disease is 
characterized by persistent hyperglycemia due to loss of pancreatic β cells, cells 
that release insulin to control blood glucose and are located in the islets of 
Langerhans (islets). Islets are polyhormonal organoids comprised of β cells along 
with several other important endocrine cell types, which are organized in 
spheroids of around 100 µm diameter and are distributed throughout the 
pancreas (Figure 1).  
1.2 Current Treatments 
1.2.1 Exogenous Insulin injections 
Because endogenous insulin production is no longer sufficient to control blood 
glucose, standard therapy for T1D patients consists of daily injections of 




insulin with improved safety and tunable absorption rates. However, manual 
exogenous insulin therapy is burdensome and often succeeds only in delaying 
the onset of morbidity, such as kidney disease and retinopathy, because of large 
fluctuations in blood glucose. Recent decades have seen decreases in mortality, 
due in large part to improved blood glucose sensors and protein engineering 
technologies [6]. However, dangerous, and potentially fatal, hypoglycemic states 
are possible when too much insulin is administered. Bolus delivery of insulin 
results in large blood glucose concentration fluctuations, even when slow 
absorbing insulins are used. Insulin pumps with transdermal catheters can 
provide a slow infusion of insulin, minimizing frequency of large fluctuations in 
blood glucose. Strategies to enforce closed loop control of blood glucose by 
integrating glucose sensor with insulin pumps are becoming practical, and a 
recent commercially available insulin pump has semi-autonomous insulin delivery 
capabilities when integrated with a compatible transdermal blood glucose monitor 
(Medtronic MiniMed). Any viable cure for T1D must include closed loop 
regulation of blood glucose to avoid hypoglycemic episodes and prevent wild 
fluctuations in glucose levels. Transdermal systems are often painful for patients 
and cannot recapitulate endogenous insulin response kinetics, but the closed-





Figure 1. Pancreatic islets are endocrine organoids that regulate blood glucose 
by releasing insulin in the presence of glucose. Islets are composed of several 
cell types which are defined by the hormones they secrete, including insulin 
producing β cells, glucagon producing alpha cells, and somatostatin producing 
delta cells. Figure adapted from public domain material [7] 
1.2.2 Transplantation 
Transplantation of allogeneic islets can potentially provide such regulation, 
and can provide temporary independence from exogenous insulin therapy [8, 9]. 
In fact, both whole pancreata and purified islets have been transplanted to 
successfully reverse diabetes [10, 11]. While whole pancreas transplant is about 
as effective as islet transplant, limited supply of pancreata exclude this procedure 




1.2.2.1 The Edmonton Protocol 
The Edmonton Protocol [9], an optimized islet transplant procedure 
developed for humans, was put into use in 2000, and was the first demonstration 
of purified islets being used to reverse T1D in humans. In this procedure, islets 
isolated from multiple cadavers are infused into the liver through the hepatic 
portal vein, where they lodge and produce insulin in response to increasing blood 
glucose (Figure 2). This important proof of concept enabled seven patients to 
achieve 100% insulin independence initially. However, after 9 years, the same 
group had only 15% insulin independence, but 73% of transplanted subjects still 
had detectable C-peptide [13]. In a separate study of 36 patients that received 
islet transplants according to the Edmonton Protocol, 21 patients achieved insulin 
independence, and of these only 5 were still insulin independent after 2 years 
[13]. Although the optimized immunosuppressive prescribed by the Edmonton 
Protocol have resulted in little to no instance of opportunistic infections, cancer, 
or lymphoproliferative disease[13], long term immunosuppression does 





Figure 2. Schematic illustrating intra-hepatic islet transplantation in humans. 
Islets are purified from cadaveric pancreata and are infused into the hepatic 
portal drainage of recipients. Islets lodge in the liver and provide endocrine 
function. Figure adapted from public domain material [7]. 
 
1.2.2.2 Improved Protocols 
Since the development of the Edmonton Protocol, intrahepatic 
transplantation of islets has expanded, with new protocols being developed, 
which overcome limitations of the Edmonton Protocol, particularly those 
associated with immunosuppression. Recently, the Collaborative Islet Transplant 




that received 1679 infusions of islets between 1999 and 2012. These data 
demonstrate a remarkable improvement in the rate of insulin independence of 
islet graft recipients during this period.  Insulin independence after 3 years was 
27% from 1999-2002, 37% from 2003-2006, and 44% from 2007-2010. 
Moreover, other indicators of islet graft function were better maintained in 2007-
2010 when compared with earlier transplants, including resolution of severe 
hypoglycemic episodes, reduction of HbA1c, and stabilization of blood glucose 
[15]. Recent reports of successful transplantation from various European groups 
particularly demonstrate the efficacy of improvements over the Edmonton 
Protocol. In a study by the UK islet transplantation program, 80% of islet 
transplant recipients still maintained graft function after two years, and 70% 
maintained HbA1c less than 7% [16]. Even more excitingly, two other European 
studies reported insulin independence in 50% and 75% of patients a full 5 years 
after islet transplantation [17, 18]. The progress that has been made in improving 
islet transplantation in the last 15 years is due largely to improvements in both 
induction and maintenance immunosuppressive regimens, which improve islet 
engraftment and viability, both by possessing lower toxicity to islets and by 







1.3 T1D Disease Progression 
Optimizing immunosuppression is particularly important in clinical islet 
transplantation because recipients have primed autoreactive responses against 
islet antigens in addition to the allogeneic antigens that necessitate 
immunosuppression in the context of solid organ transplantation [20].  Any 
strategies to mitigate immune responses to allografts must address both forms of 
rejection, so an understanding of their underlying mechanisms is important. 
Onset of T1D begins with autoantibody production, followed by infiltration 
of innate and adaptive immune cells into islets, which form islet lesions and 
produce insulitis, or inflammation of the islets. Studies have indicated that 
autoimmune destruction of islets requires macrophages as well as CD4+ and 
CD8+ T cells [21-23], but when these cells are in islet lesions they are not 
destructive until an unknown triggering event occurs [24], which initiates the 
autoimmune destruction of β cells. Dominant autoantigens responsible for islet 
rejection are associated with β cell components, specifically insulin, glutamic acid 
decarboxylase 65 (GAD65), and islet-cell antigen-2 (IA-2) have been identified as 
primary players [25]. Insulin is the first target for autoantibodies detectable during 
the onset of T1D [26], but during the progression of disease, autoantigen epitope 
spreading occurs [27]. This process begins when the immune system recognizes 
and responds to an antigen with a single epitope, and spreads over time as the 
immune system recognizes new epitopes of the same antigen, as well as wholly 




with an increase in both autoantigens and in autoantibodies [25]. During the 
progression of T1D, macrophages invade islets and are activated to produce 
asymptotic inflammation via an unknown mechanism. Activated macrophages 
are required for the progression of T1D, because they secrete inflammatory 
cytokines and act as antigen-presenting cells (APCs), activating local effector T 
cell populations against β cell-specific antigens [24, 28]. Death of β cells in islet 
lesions results in a higher concentration of autoantigens for presentation, and 
exacerbates cell-mediated islet destruction in a feedback cycle [29].  
Even without primed autoimmune responses, recipients of islet transplants 
would promptly reject the graft due to alloreactive immunity. Alloantigens may be 
recognized by T cells utilizing two mechanisms – direct and indirect alloantigen 
recognition. In direct recognition, donor tissue dendritic cells, expressing 
allogeneic MHC and costimulatory activity, migrate to lymph nodes and stimulate 
alloreactive T cells endogenous to the host [30].  In indirect recognition, host 
dendritic cells process allogeneic proteins from the graft, and trigger a T cell 
response by presenting processed antigens via MHC class I or MHC class II. The 
difference in these mechanisms lies solely in the source of the APCs, and both 







1.4 Native Islet Microenvironment 
During the process of pancreatic islet isolation, islets are removed from 
their native microenvironment. It is important to understand the critical facets of 
this environment that support islet function and health so that these aspects can 
be recapitulated when delivering purified islets in a transplantation setting. 
1.4.1 Vascularization 
Cumulatively, islets make up only about 1-2% of pancreas mass, but they 
receive about 15% of the blood supplying the pancreas [31, 32]. This 
disproportionate supply of blood suggests the importance of islets. In addition to 
receiving more blood, islets are themselves highly vascularized, containing 
fenestrated capillaries organized into a glomerular-like network, which make up 
8-10% of islet volume [33, 34]. In fact, the number of fenestrae is approximately 
10 times higher in islets that in exocrine pancreatic capillaries, islet capillaries 
have 20-30% larger diameter that exocrine pancreatic capillaries, and vascular 
density is higher for islets than the exocrine pancreas [35]. Capillary fenestrations 
and increased blood supply to islets facilitate rapid sensing of blood glucose as 
well as rapid release of insulin into circulation. In order to recapitulate healthy 
glucose kinetics in transplant recipients, rapid transport of glucose and insulin 






Acetylcholine is necessary for pancreatic β cell function [36, 37], and until 
recently, prevailing wisdom suggested that the endocrine pancreas is highly 
innervated by the autonomic nervous system, directly stimulating insulin release. 
Requirements for innervation would place more hurdles in the path of successful 
islet transplantation. Preliminary studies of islet innervation did show extensive 
nerve networks forming throughout islets and demonstrated their direct 
cholinergenic action, but these studies were performed in mice. Similar studies in 
human islets showed that islets are only slightly innervated, but that the 
sympathetic nervous system innervates smooth muscle cells in blood vessels 
surrounding islets [38]. In 2011 it was shown that the required cholinergenic input 
to β cells is provided in a paracrine fashion by α cells in humans [39], eliminating 
a potentially difficult requirement for innervation of islet grafts. In fact, these 
studies not only show innervation is not critical in human islets, they further 
demonstrate the biological priority that is placed upon controlling blood supply to 
islets. 
1.4.3 Cell-ECM Interactions 
In the healthy pancreas, islets are each surrounded by a capsule of 
extracellular matrix. This capsule has been shown to have a composition 
consistent with basement membranes which function as barriers to infiltrating 




which are known to bind to integrin receptors and facilitate adhesion and 
signaling make up the capsule, including several laminin isoforms (α1, β1, γ1, α2, 
β2), perlecan, and collagen type IV α1, but not including collagen type IV α3-6 
[41, 42]. Studies have shown that for transplanted islets to survive, adhesive 
interaction with ECM is required, suggesting that the basement membrane 
provides important signaling cues to islets in addition to providing a barrier to 
infiltrating immune cells [43, 44]. Isolation of pancreatic islets is facilitated by 
enzymatic digestion, and thereby destruction, of the basement membrane which 
surrounds islets. Therefore, delivery strategies for islet transplantation should 
strive to restore important cell-ECM interactions that are lost during isolation in 
an effort to prolong islet survival and function. Motivated by this logic, several 
investigations have found that presentation of cell adhesive peptides on 
biomaterials can enhance islet viability and function [45, 46]. Several cell 
adhesive peptides, including RGD, GFOGER, and IKVAV [45] (derived from 
fibronectin, collagen and laminin, respectively) have been identified in these 
studies as useful for enhancing islet survival and/or function in vitro. 
 
1.5 Transplant Site 
1.5.1 Intrahepatic 
Although the intra-hepatic site is the current clinical standard for islet 




resulting from instant blood-mediated inflammatory reaction (IBMIR) from platelet 
and complement activation. Therefore, to avoid this graft failure, new sites should 
be investigated for clinical islet transplantation. Clinical trials utilizing the 
Edmonton Protocol with intrahepatic allogeneic islet transplantation have 
demonstrated insulin independence in diabetic patients, but the median duration 
of insulin independence is only 35 months and requires multiple donor pancreata 
[47].  The intrahepatic site is accessible laproscopically for islet delivery, but the 
hepatic vasculature is an inhospitable transplant site, as evidenced by 
suboptimal performance of autoislet grafts [48, 49]. Rapid IBMIR to intraportally 
infused islets contributes to extensive graft deterioration [50-52], with  
approximately 50-60% of transplanted cells being lost immediately [53], and 
further islet destruction is mediated by both innate and adaptive immune 
responses, even when chronic immunosuppressive regimens are used[15]. Islets 
transplanted intrahepatically are also gradually deteriorated by fibrotic 
encapsulation, toxicity due to immunosuppressant drugs, and glucolipotoxicity 
[54-56]. Cumulatively, the stresses from intrahepatic islet delivery produce high 
rates of islet engraftment failure, so islets from 2 to 3 donors must be 
transplanted in each recipient to achieve insulin independence [57]. In addition to 
the hostile nature of the intravasculature site due to direct exposure of islets to 
blood, islet performance may be further decreased by a lack of cell adhesive 
protein binding sites in islet microenvironment, which have been shown to 




1.5.2 Alternative Transplant Sites 
Various alternative transplant sites do not expose islets directly to 
circulating blood, and so have been explored to avoid IBMIR-instigated graft loss. 
These sites include the subcutaneous space [58-62] and intraperitoneal tissue 
that is laparoscopically-accessible such as the small bowel mesentery (SBM) [63, 
64] or omentum [65-68]. These extrahepatic sites are appealing due to ready 
accessibility, but each of these tissues presents varying degrees of vascular 
supply and inflammatory responses, which are known to influence islet survival, 
engraftment, and function [69-71]. Preclinical models have demonstrated that re-
establishment of blood flow to islets requires several days to weeks when using 
intraportal, renal subcapsular, or splenic subcapsular sites [72-74]. During this 
period, the local islet environment has reduced oxygen tension and a vascular 
bed with lower vessel density than the native pancreas [75, 76]. This slow, 
insufficient revascularization of transplanted islets is a major cause for reduced 
islet viability and function [77-79]. Delivery of pro-vascularization factors utilizing 
genetic manipulation of islets has improved vascularization and islet function [80-











While vascularization of transplanted islets improves their function and 
survival in syngeneic transplant scenarios, vascularization also facilitates 
exposure of islet grafts to the host immune system, possibly exacerbating 
rejection by auto- and allo-immune mechanisms, especially in the absence of 
systemic immunosuppression. With the ultimate goal of eliminating the 
requirement for systemic immunosuppression along with its associated side 
effects, it has been proposed that transplanted islets be protected from the host 
immune system using permselective (semi-permeable) membranes. This 
approach, known as immuno-isolation, requires membranes that have a pore 
size designed to simultaneously accomplish two tasks. First, the membrane pore 
size must be large enough to allow the relatively unhindered transport of small 
molecules and proteins, so that nutrients can be supplied to the islets while 
waste products and insulin rapidly diffuse away. Second, the membrane pore 
size should be small enough to exclude larger immune system components, 
including antibodies and immune cells (Figure 3). While there is no perfect cutoff 
size at which functional molecules transport easily and all immune components 
are excluded, preventing cell-cell contact of the islets with immune cells will 
undoubtedly mitigate damage to the graft, and may reduce immunosuppressive 





Figure 3. Microencapsulation of cells can provide an immunoprotective effect 
while facilitating cell function. By tuning pore size of the hydrogel network, 
antibodies and immune cells can be excluded from the microcapsule, while 










1.6.2 Immunoisolation Devices 
1.6.2.1 Intravascular Macrodevices 
Attempts at immuno-isolation over time have taken several form factors, 
each of which has inherent advantages and disadvantages. Early immuno-
isolation devices were intravascular and were partially comprised of a tubular 
semi-permeable membrane that was required to be surgically implanted by 
vascular anastomoses so that blood circulated through its lumen [87, 88] (Figure 
4). Excellent transport of nutrients and oxygen is achieved with these devices, 
but the risk associated with the surgical operation and likelihood of post-operative 
thrombosis are major practical limitations the the intravascular approach. Since 
the 1990s, immuno-isolation has focused on extravascular devices, which are not 
as risky and invasive as devices which contact the blood, but are more likely to 





Figure 4. Immuno-isolation devices with various forms have been investigated. 
Early intravascular devices required invasive surgical implantation, and so were 
not clinically practical. Later, safer extravascular devices were explored, 
generally consisting of a polymer, usually a hydrogel, into which cells were 
embedded. By reducing thickness of membranes, diffusion of critical nutrients 




1.6.2.2 Extravascular Macrodevices 
Extravascular macrodevices comprise macrocapsules, as well as planar 
and tubular membranes with a variety of configurations. These devices are the 
most widely tested in the clinic because they are easily retrievable in case of 
complications. Unfortunately, because of a low surface area to volume ratio in 
these devices, poor diffusion of oxygen and nutrients usually lead to cell necrosis 
and loss of function. In the clinic, these effects are often exacerbated by the 
selection of poorly vascularized sites, with subcutaneous implantation. A benefit 
of subcutaneous implantation is that non-functional devices can be explanted 
and replaced in a minor operation. A promising insulin producing extravascular 
macrodevice is being developed by TheraCyte[89], who claim that their device 
functions for 6 months when implanted subcutaneously.  
1.6.2.3 Extravascular Microcapsules 
Extravascular microcapsules are generally comprised of hydrogel spheres 
with diameter less than 1mm which contain cells or cell clusters [90]. 
Microcapsules have drastically higher surface area to volume ratio than 
macrodevices and therefore improved transport kinetics of oxygen and nutrients, 
which promotes survival of encapsulated cells. The major downside to this 
approach is that microcapsules are difficult to retrieve in case of post-operative 




ensure that microcapsules do not aggregate because this can result in necrosis 
and graft failure [91].  
1.6.2.4 Conformal Coating 
Finally, conformal coating of cells has been used to increase the surface 
area to volume ratio of grafts even more, facilitating even better mass transport 
than in microcapsules [92]. The smaller size of these constructs also enables the 
use of space-constrained transplant sites, including intra-hepatic. While many 
different approaches have been used to apply conformal coatings to cells, 
uniform coverage of all cells is usually questionable and most coatings are gone 
within a few days [93, 94]. For the most part, current efforts at conformal coating 
have been of limited use for long term immuno-isolation. 
 
 
1.7 Polymers for Microencapsulation 
Because of necrosis associated with hypoxic cores in macrodevices and 
because of limited persistence of conformal coating, microencapsulation is the 
most promising strategy for achieving immuno-isolation. While other classes of 
materials have been investigated for immuno-isolation, polymers, especially 
hydrogels, can also be designed to simultaneously recapitulate important aspects 
of native cell microenvironment. Polymers employed in this application must 




gelation of microcapsules under cytocompatible conditions, and must retain 
mechanical integrity for the life of the graft, in vivo. Additionally, microcapsules 
should not elicit a strong foreign body response in the recipient, and they would 
ideally allow for recapitulation of the native islet microenvironment when possible.  
Synthetic as well as naturally occurring hydrogels have been explored for 
immuno-isolation. Biologically derived hydrogels include gelatin, fibrin, hyaluronic 
acid, agarose, chitosan and alginate. Synthetic polymers which have been 
utilized include poly vinyl alcohol, poly lactic acid, poly glycolic acid, polypeptides, 
and polyethylene glycol, as well as a plethora of functional derivatives of these 
polymers [95-97]. While natural polymers are known to provide signals to cells 
that promote survival in vivo, the nature of these interactions is poorly defined, 
and they are difficult to modify. Conversely, synthetic polymers provide 
consistent, well defined compositions and their production is scalable. 
Additionally, synthetic polymers can be functionalized with a variety of reactive 
groups, including click chemistries which allows for functionalization and gelation 
in complex physiological milieu.  
1.7.1 Alginate 
Alginate has emerged as the dominant material reported for cell 
microencapsulation, largely due to its apparent biocompatibility and ease of 
gelation. Other natural materials investigated have not reached the level of 




microcapsules is limited by several factors. Depending on the source of alginate, 
its composition, and thereby functional properties, vary significantly [99]. In 
addition to its source, the extraction and purification processes utilized for 
alginate can drastically alter many of the properties of alginate, including 
hydrophobicity, immunogenicity, viscosity [100], by altering the amount of 
contaminants present such as polyphenol, endotoxins, and proteins.  
1.7.2 Alginate-PLL 
Alginate does not inherently provide an easy mechanism for tuning 
permeability, as required in immuno-isolation applications. Negatively charged 
alginate microcapsules are generally coated with a polycation (usually poly-L-
lysine) for stability and to control the molecular weight cut off of the membrane 
more precisely [101, 102]. While poly-L-lysine (PLL) coatings enable tuning of 
membrane permeability, they are also known to be immunogenic, which is 
counterproductive in immuno-isolation applications [103]. Microcapsules often 
undergo a final coating with alginate so that the final structure is alginate-PLL-
alginate (APA), but studies suggest that external alginate is not sufficient to mask 
the immunogenicity of PLL. Indeed, APA microcapsules activate complement, 
induce cytokine production by macrophages, and elicit an exacerbated 
pericapsular response when compared to alginate-only microcapsules. Alginate 
microcapsule technology has been extensively developed, beginning more than 
30 years ago, but still faces technical hurdles, especially relating to sourcing and 




clinical deployment unlikely. However, some alginate derivatives have recently 
been identified which elicit minimal foreign body response in vivo, and allogeneic 
stem cell-derived β cells delivered microencapsulated in these alginates could 
restore long term glycemic control in immune-competent diabetic mice [104, 
105]. 
1.7.3 Synthetic Polymers 
Scalable production of high-purity synthetic polymers can be 
accomplished with current technology, and some chemistries utilized enable 
stoichiometric incorporation of bioactive moieties and independent control of 
permeability. Polyethylene glycol (PEG), known for its low-protein adsorption and 
minimal inflammatory profile, is the gold standard synthetic hydrogels, and 
hydrogel properties can be altered by changing macromer structure, molecular 
weight, and end group functionalization. Bioactive hydrogels are usually 
crosslinked with either Michael-type addition reactions or acrylate polymerization 
[106]. Early synthetic hydrogels were largely based on PEG diacrylate chemistry, 
which are crosslinked via free-radical initiated polymerization of acrylate 
functional groups. Free radicals generated either through chemical activation or 
cleavage of photoinitiators with UV irradiation can rapidly crosslink hydrogels, but 
exposure of cells to free radicals decreases encapsulated cell viability. More 
recently, branched PEG macromers have been utilized, which contain 4- or 8- 
arms that are terminated with functional groups - acrylate[107, 108], vinyl-sulfone 




others[112]. Each of these reactive end groups can be used to tether bioactive 
moieties, enabling covalent incorporation of cell adhesive peptides and growth 
factors into hydrogels. A comparison between 4 arm macromers terminated with 
these functional end groups showed that 4-arm PEG maleimide (PEG-4MAL) 
had improved cross-linking efficiency, bioligand incorporation, and encapsulated 
cell viability [113]. Reproducibility of hydrogel structure and properties, along with 
stoichiometric control of bioactive moiety presentation, are major advantages of 
synthetic hydrogels (particularly PEG-4MAL) over alginate. Alginate solutions 
have relatively high surface tension in water, and their crosslinking is 
accomplished through diffusion of very small cations, so it occurs rapidly enough 
that aqueous phase droplets can be crosslinked cytocompatible aqueous buffers. 
This method cannot be utilized to crosslink droplets of PEG-4MAL solutions, 
because they crosslink more slowly than alginate and disperse before gelation 
can occur. Therefore, new techniques must be developed for the fabrication of 
synthetic hydrogel microcapsules. 
Incorporation of important biological molecules can be easily 
accomplished with some synthetic hydrogels, such as those containing 
vinylsulfones and maleimides, which react with thiol-containing molecules to form 
a covalent bond. Because the amino acid cysteine contains a thiol reactive 
group, peptides and proteins which contain cysteine residues can be covalently 
bonded to hydrogels. This is a major benefit over alginate because it enables a 




adhesive peptides and proteins can be incorporated stoichiometrically and 
presented to encapsulated cells. Many cell types require adhesive cues to 
survive and proliferate, and the effect of adhesive ligands on β-cell function and 
proliferation has been shown to be significant [45, 114]. Facile incorporation of 
adhesion molecules is only one benefit of synthetic hydrogel chemistry – another 
being the ability to control crosslinker size and stability. Dithiol molecules can be 
used to crosslink multi-arm PEG-MAL and PEG-VS, and by controlling the 
degradation mechanism and rates of these crosslinkers, tissue ingrowth and 
implant engraftment may be enhanced. In fact, several different dithiol peptide 
crosslinkers have been identified which are protease degradable, and crosslink 
synthetic hydrogels which have tunable degradation rates and  MMP specific 
degradation [115, 116]. By allowing for host cell adhesion and infiltration, these 
synthetic hydrogels allow tissue ingrowth that cannot occur with alginate, which 
could result in better engraftment of implanted cells or tissues. 
 
1.8 Droplet Templated Microgels 
By definition, microencapsulation involves structures under 1 mm in size, 
so functional grafts must be comprised of many microcapsules. A high 
throughput method exists for the production of alginate microcapsules, in which 
droplets containing cells are produced by extrusion through a needle, and are 




this technique is not amenable to the production of hydrogel microspheres, or 
microgels, with different chemistries. Direct templating of microcapsules on a 
large scale, through microfabrication of molds into which gels can be cast, is a 
viable method that has been explored with some synthetic polymers, but 
throughput is severely limited by the size of molds and by handling 
considerations. Therefore, a scalable approach for the micro-encapsulation of 
cells and islets is required before modern synthetic polymers can be utilized for 
delivery of clinically relevant cell numbers in transplant scenarios. 
Indirect templating of microcapsules in immiscible oil through droplet 
microfluidics could allow for continuous, rather than batch, production of 
microcapsules. In continuous droplet microfluidics, fluid flows cause the breakup 
of liquid droplets, and an immiscible carrier phase (liquid or gas) is used to 
separate and stabilize droplets. Droplet diameter can be controlled by varying 
channel geometry as well as fluid flow rates in these devices, and droplet 
populations are generally uniform in size, with low polydispersity [117-119]. This 
control can be utilized to minimize immune response and fibrous overgrowth of 
microcapsules, because microcapsule size has been correlated with host 
response in vivo [120].  
Droplet microfluidics has enabled the production of crosslinked hydrogel 
spheroids (microgels) with varied chemistries and utilizing differing methods of 
crosslinking. Microfluidic droplet templating has been applied to alginate and 




continuous phase in order to utilize size control that is not possible with extrusion 
techniques [121]. Chemically crosslinked microgels have also been produced on 
microfluidics, by emulsifying aqueous solutions of monomers and subsequently 
inducing crosslinking in these compartmentalized droplets. This approach has 
been used to photopolymerize microgels made of various synthetic polymers, 
including PEG-DA [122], and acrylamide [123] among others [124, 125]. 
However, this approach limits production of microgels to polymers that can be 
photo-crosslinked, which disqualifies polymers which are more amenable for 
functionalization with bioactive moieties, such as PEG-4MAL. Moreover, UV 
radiation and free radicals are harmful to cells, and so are not ideal for 
crosslinking cell-laden microcapsules. Another mechanism that has been 
employed for droplet-templated microcapsule production is to first generate 
droplets containing either polymer precursor or crosslinker, and then to force 
coalescence of droplets and subsequent hydrogel formation [126]. Modifications 
of this approach might allow the production of microgels in modern synthetic 
polymers, but control of stoichiometry of droplets will be difficult if cell 









The immuno-isolation potential of microcapsules is determined by the pore 
size cut off of the membrane formed by encapsulating hydrogels. Molecular 
weight cut off of PLL-alginate microcapsules can be controlled by changing PLL 
molecular weight and coating method [127], but even so, no alginate 
microcapsules have been demonstrated to reliably mitigate rejection in immune-
competent animals.  Therefore, some form of additional immuno-modulation will 
have to be deployed for long term graft acceptance. Microencapsulation has 
demonstrated synergistic effects with traditional immunosuppression, which 
could reduce the dose of immunosuppression as well as associated side effects. 
However, local immunomodulation at the site of the transplant could eliminate the 
requirement for systemic immunosuppression, and make transplantation a 
sensible therapy for a much larger number of patients. Several approaches have 
been investigated for local modulation of the immune response around tissue 
grafts, including co-transplantation of mesenchymal stem cells (MSCs), as well 
as presentation of various immune-regulatory proteins, either through direct 
display or genetic engineering of transplanted cells. Because graft acceptance is 
strongly correlated with FoxP3+ T reg cells in the graft microenvironment, these 






1.9.1 MSC Co-Delivery 
MSCs may improve graft acceptance through the modulatory effects they 
exert on various immune cell populations, and they may also improve islet 
function [130]. Immune-privileged status conferred by a lack of MHC class II and 
other costimulatory molecules allows allogeneic MSCs to be transplanted without 
being rejected, and MSCs effects on immune cells are powerful. MSCs inhibit T 
cell activation and proliferation [131, 132] through the induction of 
CD4+CD25+FoxP3+ regulatory T cells [133], and through the induction of 
regulatory APCs [134]. MSCs also alter the cytokine secretion profile of APCs, 
decreasing the production of inflammatory tumor necrosis factor α (TNF-α), while 
increasing the production of anti-inflammatory IL-10 [135]. B lymphocyte 
proliferation, differentiation, and antibody production are all impaired by co-
culture with MSCs [136], demonstrating the various immunomodulatory effects of 
MSCs. In nonhuman primates, co-transplanted MSCs have been shown to 
increase the percentage and number of FoxP3+ T regulatory cells [137], 
suggesting that effects on immune cells that were observed in vitro are robust. 
However, more studies are needed to determine whether the immunomodulatory 
effects of MSCs are capable of mitigating the severe auto- and allo- reactive 
immune rejection of co-transplanted islets in vivo, as well as the ideal delivery 





1.9.2 Protein and Gene Delivery 
Another approach to immunomodulation is presentation of 
immunomodulatory proteins, such as transforming growth factor β (TGF-β) and 
fas ligand (FasL), either locally along with grafts, or systemically. TGF- β1 is an 
immune signaling molecule that plays an important role in maintenance of, and 
the induction of, Treg cells, because mice deficient for TGF-β1 consistently have 
reduced numbers of this important immune suppressor cell [138]. Ectopic TGF-β 
expression in allogenic heart grafts resulted in long term survival, demonstrating 
the in vivo efficacy of TGF-β therapy. Systemic TGF-β therapy is associated with 
increased fibrosis of transplants, but immobilization of TGF-β on transplanted 
tissue may potentially reduce this fibrosis. Although mechanistic studies suggest 
the promise of TGF-β as an immunomodulatory signal, effective allograft 
acceptance through TGF-β therapy remains to be demonstrated. Another protein 
which has been utilized for immunomodulation is FasL. FasL plays an important 
role in activation-induced cell death, which is a major mechanism of immune 
homeostatis [139, 140]. Ectopic expression of FasL has been successfully 
utilized to induce hyporesponsiveness to allogenic antigens in vivo, and 
transfusion of DCs ectopically expressing FasL prolonged survival of fully MHC-
mismatched cardiac allografts [141]. Genetic transfer of FasL in renal allografts 
also resulted in prolonged graft survival in rats, suggesting the potential for 
localized FasL modulation that does not require systemic administration of this 




effective local immunomodulation, ectopic expression of proteins is technically 
challenging, and imposes severe safety concerns. Therefore, new delivery 
vehicles are needed to fully investigate the potential of immunomodulatory 
proteins for achieving allogenic graft acceptance. 
 
1.10 Summary of early studies utilizing PEG-4MAL for islet delivery 
Dr. Edward Phelps, a García lab alumnus, developed a hydrogel system for 
enhancing vascularization and function of implanted pancreatic islets utilizing 
PEG-4MAL macromer cross-linked with protease degradable peptides which 
delivered VEGF in response to cell activity at the transplant site [143]. The 
maleimide reactive group is extensively used in peptide bioconjugate chemistry 
because of its fast reaction kinetics and high specificity for thiols at physiological 
pH. Simple co-incubation of macromer with thiol - containing molecules at pH 7.4 
results in a Michael-type addition reaction that forms a covalent bond (Figure 5). 
Maleimide-based cross-linking of PEG hydrogels has significant advantages over 
other cross-linking chemistries, namely well-defined hydrogel structure, 
stoichiometric incorporation of bioligands, increased cytocompatibility, improved 
cross-linking efficiency, and tunable reaction time scales appropriate for in situ 
gelation for in vivo applications [143]. Additionally, the base macromer exhibits 
minimal toxicity and inflammation in vivo and is rapidly excreted via the urine 




translational potential of these hydrogels. Hydrogels cross-linked by protease-
degradable cross-links have been engineered as protein delivery vehicles with 
controlled, on-demand release profiles for protein therapeutics, including the 
vasculogenic agent VEGF [63, 144, 145]. 
 
 
Figure 5. PEG-4MAL Macromer consists of a 4-arm branched PEG backbone 
that has been modified with a maleimide group terminating each arm. At 
physiological pH, free thiol-containing molecules undergo a Michael-type addition 
reaction with maleimides, forming a covalent bond to macromer. This reaction is 
facilitated by a nucleophilic buffer such as triethanolamine, and can be used to 
either functionalize the macromer or crosslink macromer into a hydrogel network. 
 
While I was in a supporting role on this project, Dr. Phelps developed 
these vasculogenic hydrogels and utilized them to deliver islets to an alternative 
delivery site, the small bowel mesentery (SBM), successfully reversing diabetes 
in a syngeneic murine model [63]. The SBM is a thin tissue which connects the 




allowing for the transplantation of islets very near existing vasculature. 400 bare 
islets were immobilized on the mesentery surface by suspending them in PEG-
4MAL that had been functionalized with 2.0 mM RGD and 10 µg/mL VEGF, and 
subsequently adding 2.6 mM of a degradable peptide crosslinker (VPM) before 
pipetting mixture onto the mesentery. Within 5 minutes, a crosslinked gel had 
formed, adhering islets to the mesentery surface. After 4 weeks, animals were 
injected with lectin to label vasculature and were sacrificed. Figure 6B shows an 
image of a transplanted islet graft and the extensive vascularization that had 
occurred after 4 weeks in vivo. Vascularization of this graft, along with several 
controls, was quantified by vessel area (lectin positive) over total islet area 
(Figure 6C). While the PEG-4MAL + VEGF delivery system had less 
vascularization than native islets, there was a statistically significant improvement 







Figure 6. Rapid and extensive revascularization occurs in islets delivered to the 
SBM using our engineered vasculogenic hydrogel. (a) Islets are isolated from 
donors using standard methods, and are adhered to the SBM of diabetic 
recipients using PEG-MAL + VEGF. (b) Extensive engraftment of the transplant 
occurs in 28 days, (c) resulting in significantly more intraislet vessels than islets 








Rapid revascularization is important for improving islet engraftment, but 
the restoration of euglycemia is the ultimate metric for islet transplant strategies. 
Therefore, blood glucose was monitored daily for the mice receiving 400 islets at 
various sites. All treatment groups received streptozotocin (STZ) injections 2 
weeks prior to transplant, and all animals were stably diabetic (>250 mg/dL blood 
glucose) on day 0. Euglycemia was restored in the PEG-4MAL + VEGF animals 
on day 16 after receiving a 400 islet transplant, but transplants in the hepatic 
portal vein failed to reverse diabetes within 28 days (Figure 7). A peritoneal 
glucose challenge was performed on day 28, and again, only the healthy animals 
and those receiving SBM grafts with PEG-4MAL and VEGF had blood glucose 
levels below 250 mg/dL after 3 hours. Finally, serum C-peptide levels on day 28 
measured using ELISA showed that more insulin was being produced in animals 
receiving a SBM graft than in those receiving an intrahepatic graft. Taken 
together, these results indicate that the SBM is a promising site for islet delivery, 
especially when transplants are delivered with biodegradable PEG-4MAL 





Figure 7. Delivery of pancreatic islets to the SBM in degradable PEG-4MAL gels, 
functionalized with VEGF and RGD, restores euglycemia in a syngeneic murine 
model. (a) 400 islets delivered to the SBM reverse diabetes, while 400 islets 
delivered through the hepatic portal vein were unable to restore euglycemia (n=4-
6) in a streptozotocin diabetes model. (b,c) Serum C-peptide levels and IP 
glucose challenge response on day 28 after transplantation further demonstrate 
the superior function of islets delivered to the SBM with our vasculogenic 






1.11 Research Summary 
  Permselectivity of microgels which encapsulate cells can provide 
immunoprotective effects as demonstrated by studies utilizing alginate-PLL 
coatings on pancreatic islets. Due to their high surface area to volume ratio, 
microgels also reduce mass transport limitations of encapsulation compared to 
bulk hydrogel encapsulation. Alginate microgels have controlled permselectivity, 
but synthetic hydrogels may additionally be covalently functionalized with 
bioactive molecules in order to support encapsulated cell survival and function, or 
to provide instructive cues to the host, functions not readily accomplished with 
alginate. Specifically, PEG-4MAL possesses versatile utility as a cell 
encapsulant, and can be used to instigate functional vascularization of 
encapsulated pancreatic islets when functionalized with VEGF.  Permselectivity 
alone may not provide enough protection to eliminate immune rejection of 
encapsulated cells, so the ability to deliver bioactive moieties may enable active 
modulation of the immune response.  Unfortunately, the extrusion fabrication 
method that has been used to produce alginate microgels for decades is not 
compatible with covalently crosslinked synthetic hydrogels, and is not well suited 
to producing cell-laden microgels below 250 µm diameter. Therefore, new 
methods are needed to microencapsulate cells in synthetic microgels, ideally with 
controlled size. 
 The work presented here describes an enabling tool for the encapsulation 




refinements of this technology. The format of chapters may not be uniform, 
because each chapter is compiled from a separate manuscript intended for 
independent publication. Chapter 2 describes the development of a microfluidic 
platform capable of encapsulating cells and pancreatic islets, as well as 
generating monodispersed microgels. Chapter 3 describes the optimization of 
pancreatic islet microencapsulation in PEG-4MAL, and develops a unique 
strategy for in vivo delivery. Chapter 4 describes the development of a strategy 
for active immunomodulation by simple co-delivery of unmodified islets with 
microgels presenting an engineered FasL protein in diabetic mice. Chapter 5 
breaks from the theme of diabetes and instead describes a two-layer elastomeric  
microfluidic device with parallelized encapsulators for increased throughput when 
encapsulating cells in small microgels. Together, these accomplishments both 






CHAPTER 2: MICROFLUIDIC-BASED GENERATION OF SIZE-
CONTROLLED, BIOFUNCTIONALIZED SYNTHETIC POLYMER MICROGELS 
FOR CELL ENCAPSULATION 
 
 
Text as Published in Advanced Materials [146], U.S. Patent 9,381,217 
Authors: Devon M. Headen, Guillaume Aubry , Hang Lu , and Andrés J. García  
2.1 Abstract 
Cell and islet microencapsulation in synthetic hydrogels provides an 
immunoprotective and cell-supportive microenvironment. A microfluidic strategy 
for the generation of biofunctionalized, synthetic microgel particles with precise 
control over particle size and molecular permeability for cell and protein delivery 
is presented. These engineered capsules support high cell viability and function 
of encapsulated human stem cells and islets. 
2.2 Main Text 
Hydrogel microencapsulation of cells is a promising strategy for 
immunoprotection after transplantation. Since the development of alginate-poly-
L-lysine encapsulation by Lim and Sun in 1980 [101], their approach has 
remained the standard for cell encapsulation, although major efforts have led to 




with alginate’s inherent biotolerance in vivo, have led to its prevalence,[148] even 
though the ability to control local cellular environment via incorporation of 
bioactive molecules (e.g., adhesive peptides) is limited. Highly tunable, synthetic 
hydrogel encapsulation is attractive for various regenerative medicine 
applications,[149-151] not only for immunoisolation, but also for directing cell 
behavior and fate.[149] Several groups have developed more complex 
encapsulation configurations, such as cell encapsulation in natural hydrogel 
fibers,[152, 153] but the benefits of added geometric complexity remain to be 
established. Minimization of encapsulation volume is also important in many 
regenerative medicine scenarios, including pancreatic islet transplantation. In an 
effort to reduce the high polydispersity present in electrostatically generated 
alginate droplets with diameters <200 µm,[154] microfluidic droplet generation 
has been explored.[155-157] Microfluidic devices have also been used to 
generate synthetic hydrogel particles.[122, 158-161] Even for synthetic polymer 
encapsulation, control of cellular microenvironment by functionalization of 
polymers with bioactive molecules remains a significant challenge. Current 
synthetic polymer encapsulation strategies typically rely on cytotoxic crosslinking 
mechanisms such as UV- or thermal-based free radical polymerization. Here, we 
present a facile, modular microfluidics-based technology for the generation of 
microgels of controlled size and microencapsulation of clinically relevant cells, 
such as human pancreatic islets and human mesenchymal stem cells (hMSCs). 
Peptides and proteins are also easily incorporated into 4-arm PEG maleimide 




cellular microenvironment. The PEG-4MAL hydrogel system has significant 
advantages over other hydrogel chemistries, such as well-defined hydrogel 
structure, facile and stoichiometric incorporation of bioligands, increased 
cytocompatibility, improved crosslinking efficiency, and tunable reaction 
rates.[113] Additionally, the PEG-4MAL macromer exhibits minimal toxicity and 
inflammation in vivo and is rapidly excreted via the urine,[63] which are important 
considerations in translating this material to in vivo applications. The crosslinking 
scheme for this system utilizes a Michael-type addition reaction, is 
cytocompatible, and does not rely on free radical polymerization. By varying 
device geometry and fluid flow rates, monodisperse microgels with a wide range 
of diameters can be produced. Kinetic studies of the release of microgel-
encapsulated biomolecules demonstrate not only the immunoisolation potential 
of the microgels, but also the capability of tuning critical network parameters that 
cannot be easily tuned in natural polymers, such as macromer molecular weight, 
for rate-controlled release of peptide therapeutics. Importantly, the 
microencapsulation process does not affect the viability or function of human 
pancreatic islets and mesenchymal stem cells (hMSCs). 
Pioneering studies by Thorsen demonstrated controlled generation of 
emulsions using T-junctions in microfluidic devices,[162] and the work of Stone 
established the ability to generate droplets using flow focusing microfluidic 
geometries.[163, 164] Weitz established encapsulation of cells inside emulsions 
for high throughput cell-based assays.[165] Translating this work into covalently 




because polymer precursors must be liquid while flowing through the focusing 
nozzle, but droplets must crosslink rapidly after being generated to prevent them 
from merging. Recently, synthetic polymer microgels have been generated, 
including cell-laden microgels.[122, 158-161, 166, 167] However, most of these 
schemes require crosslinking using UV-based free radical polymerization, 
resulting in potentially cytotoxic effects on encapsulated cells. Although cell 
encapsulation in synthetic microgels crosslinked without free radicals has been 
reported, the polymers utilized cannot easily be functionalized with bioactive 
molecules.[158, 166] This major limitation makes the maintenance of cells 
requiring adhesive ligands for viability and function difficult. Recently, Lutolf 
devised an elegant microfluidic scheme to generate surface-modifiable synthetic 
microgels that does not utilize free radical polymerization, but neither bulk 
modification with bioactive molecules nor cell encapsulation was shown.[160] 
Microfluidic encapsulation of large clusters of cells, such as human islets, is more 
challenging than single cell encapsulation, because the larger particles tend to 
clog microfluidic channels. For these reasons, synthetic polymer 
microencapsulation of islets using microfluidics has not been shown. To minimize 
encapsulation volume while avoiding microfluidics altogether, investigators have 
explored conformal coating of islets.[168, 169] Whereas conformal coating 
minimizes transplant volume, the immunoisolation potential of such thin polymer 
membranes remains unknown.  
To address these limitations, we generated a strategy (Figure 8) to 




functionalized with cell adhesive peptides, by producing droplets using a flow 
focusing microfluidic device and subsequently covalently crosslinking the 
droplets with the small molecule dithiothreitol (DTT). Three independent flows of 
(1) mineral oil containing SPAN80 (a surfactant), (2) a crosslinker phase 
containing mineral oil and SPAN80 with an emulsion of aqueous DTT solution, 
and (3) PEG-4MAL macromer in aqueous physiological buffer were pumped into 
the microfluidic chip using syringe pumps. As the macromer phase approached 
the flow-focusing nozzle, a co-flowing continuous phase of oil shielded the 
macromer from contact with the crosslinker-laden oil phase. Because crosslinker 
could not reach the macromer before flow instability occurred, monodisperse, 
spherical droplets were formed. The crosslinker then rapidly diffused into 
droplets, covalently crosslinking the PEG-4MAL macromer into the hydrogel 
network via Michael-type addition reaction of the maleimide groups on the 
macromer and thiols on the crosslinker. The PEG-4MAL hydrogel platform used 
for this system is easily modified with thiol-containing molecules, including 
cysteine-containing adhesive ligands and growth factors, due to the high 
specificity of the maleimide groups for thiols at physiological pH. This Michael-
type addition reaction requires no free radicals and is cytocompatible.[113] 
Furthermore, fast reaction kinetics render this hydrogel ideal for microfluidic 
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Figure 8. PEG-4MAL for microencapsulation of cells and proteins in a flow-
focusing microfluidic chip using a cytocompatible crosslinking reaction. (a) PEG-
4MAL macromer consists of a 4-arm branched PEG backbone modified with a 
maleimide group terminating each arm. At physiological pH, free thiol-containing 
molecules undergo a Michael-type addition reaction with maleimides, forming a 
covalent bond to macromer. This reaction is facilitated by nucleophilic buffers 




macromer or crosslink macromer into a hydrogel network. (b) A microfluidic 
device with flow focusing geometry is utilized to produce microgels. A co-flowing 
oil phase shields an aqueous macromer solution, containing cells and/or 
proteins, from the crosslinker-containing oil phase as the macromer solution 
approaches the flow focusing nozzle. After droplet formation, the DTT emulsion 
rapidly crosslinks macromer solution into cell- or protein-laden microgels. 
  Precise control of particle size and monodispersity are critical for many 
applications of microgels, and the microfluidic platform affords this control over a 
wide range of particle sizes. We varied macromer solution and continuous phase 
flow rates for a device with a 300 µm nozzle, and measured the corresponding 
droplet size for each flow rate (Figure 9). No cells were encapsulated in this 
application. Microgels with a wide range of sizes, ranging from 20 to 400 µm, 
could be produced on the same device; however, several flow regimes produced 
microgels with undesirable polydisperse distributions (coefficient of variation, 
CV>10%). Importantly, flow rate combinations were identified that produced a 
range of microgel sizes from 135 – 325 µm with monodisperse populations (CV< 
5%). An example of one of these flow rates is shown in figure 2, along with 
several other representative flow regimes, including one regime that does not 
produce droplets and one that produces a very polydisperse (CV = 22%) 
microgel population. Although a device with fixed geometry is capable of 
producing a wide range of particle sizes, droplets should be generated with 
diameters that are 50-100% of the nozzle width to obtain a monodisperse 




limited, because no droplets were formed for any PEG-4MAL macromer flow 
rates exceeding 50 µL min-1. If monodisperse populations of microgels are 
required that are outside the 135 – 325 µm range, the microfluidic device nozzle 
can be scaled up or down so that nozzle is roughly equal to the desired microgel 
size.  
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Figure 9. Microgel size and polydispersity can be controlled by altering 
macromer solution and continuous phase flow rates. (a) Representative images 
and quantification of microgel diameters are shown for varied flow rates. (l-r) No 
droplets are produced for PEG-4MAL flow rates of 50 µL min-1 or greater. 
Monodisperse (CV < 5%) populations can be generated for a range of sizes, one 
of which is shown here. Polydispersity is driven by a complex combination of 
factors as seen in the final 2 images. (b) Microgel diameter was measured for 
fluid flow rates that were varied for all combinations of: QPEG (µL min
-1) = 1, 5, 10, 
20, 30; Qoil (µL min
-1) = 5, 25, 50, 100; Qxlink (µL min




400. Mean and standard error were plotted as calculated from a minimum of 30 
measurements for each condition.  
 
A tunable hydrogel network with selective permeability to biomolecules is 
essential for cell microencapsulation, because antibodies and immune cells 
(relatively large objects) must be prevented from reaching encapsulated cells, 
while nutrients, signaling molecules, and waste (relatively small molecules) must 
be easily transported across the microgel capsule. Therefore, we investigated the 
suitability of our microgels for biomolecule release and cell encapsulation by 
measuring their permeability to relevant molecules of various sizes that were 
labeled with fluorescent tags. These molecules were encapsulated within 
microgels generated from a 20 kDa PEG-4MAL macromer, and the rate of their 
release into buffer was used as a metric of permeability (Figure 10a). 2-NBD-
glucose (342 Da) was rapidly released from the gels, fully equilibrating 
concentration with the buffer by the first fluorescence measurement, 5 minutes 
after swelling. Similarly, insulin-AlexaFluor488 (5.8 kDa) was rapidly released 
from the microgels upon swelling, indicating that relevant functional molecules 
diffuse quickly through the microgel. In contrast, encapsulated IgG-AF488 (~160 
kDa) was released from the microgels at a slow rate, suggesting that the 
microgel capsules are capable of preventing transport and binding of antibodies 
to encapsulated cells. Release kinetics for BSA (66.5 kDa) fell between IgG and 
insulin, suggesting that physical molecular entanglement due to the network 




results show nearly 100% release for the smaller molecules glucose and insulin. 
For the larger proteins BSA and IgG, the release did not reach 50% of the 
incorporated amount because these larger molecules remain trapped within the 
tight network structure of the PEG hydrogel. These results for reduced transport 
and entrapment of IgG support the use of these materials for immuno-
encapsulation applications. 
As a demonstration of the ability to tune network structure for protein 
release applications, we encapsulated IgG in microgels made with PEG 
macromers of different (10 kDa vs. 20 kDa) molecular weights (Figure 10b). As 
expected, the tighter network mesh of the microgels based on 10 kDa 
macromers slowed the release of IgG compared to microgels made with 20 kDa 
macromer. Because altering macromer size results in drastic changes in release 
kinetics, we expect that other parameters that influence network structure as 
related to the hydrogel correlation length, such as polymer weight % and 
crosslinking density, can be systematically varied to obtain desired release 
kinetics. Flexibility in protein encapsulation, as well as the ability to 
simultaneously control therapeutic release kinetics and particle size, render this 
encapsulation platform ideal for a wide range of protein delivery applications 
Having shown the ability to exclude high molecular weight proteins such 
as IgG with minimal impact on the transport of critical molecules such as glucose 
and insulin, we next examined cell encapsulation applications of this microgel 
system using clinically relevant cell types. Human pancreatic islets were 




were encapsulated, and 80% of microgels produced contain at least one islet), in 
microgels made from PEG-4MAL, a polymer that has been shown to support islet 
engraftment and function.[63] Encapsulated islets were maintained in culture for 
8 days with no decrease in viability (Figure 10c,d), demonstrating the capacity of 
this synthetic hydrogel network to support high viability of these sensitive human 
cells. This result also shows that any potentially cytotoxic effects of hydrogel 
precursor constituents (e.g., DTT) prior to network formation are mitigated by the 
short residence time of cells in crosslinker emulsion. The device used for islet 
encapsulation was scaled to have a 600 µm nozzle, and produced microgels 
from 300–800 µm in diameter. As a further demonstration of the versatility of this 
platform, human mesenchymal stem cells (hMSCs), currently under investigation 
for various biomedical applications due to their regenerative and 
immunomodulatory properties, were encapsulated in PEG-4MAL microgels of 
either 400 µm or 90 µm diameter. These microgels were precisely functionalized 
with a cell adhesive RGD peptide (2.0 mM) by simply reacting maleimide groups 
in the macromer with this peptide prior to cell encapsulation and hydrogel 
crosslinking. This RGD peptide supports cell adhesion, survival and function 
when incorporated into the PEG-4MAL network.[113]  After encapsulation, 
hMSCs encapsulated in both microgel sizes exhibited high viability (Figure 10e), 
and hMSCs in 400 µm diameter microgels were maintained in suspension culture 
for 7 days with no loss in viability (Figure 10f). Therefore, controlled presentation 
of adhesive peptides to cells encapsulated using a cytocompatible crosslinking 




microenvironment presenting defined bioactive peptides may be suitable not only 
for cell encapsulation and delivery,[170] but also for directing stem cell behavior 
and fate.[171, 172] Additionally, control of microgel size facilitates optimization for 
cell delivery applications. 
A crucial consideration in the engineering of microgels for cell 
encapsulation is that critical cell functions are not negatively impacted following 
encapsulation. To this end, we performed a glucose-stimulated insulin secretion 
(GSIS) assay to evaluate the function of encapsulated human islets. Bare or 
encapsulated islets were challenged with either 1.67 mM or 16.7 mM glucose for 
30 minutes, and the normalized insulin content from each group was assayed 
using ELISA. The stimulation index (SI), or ratio of normalized insulin secreted in 
high glucose group to that of low glucose group, was calculated for both bare and 
encapsulated islets. No significant difference was found between the groups 
(Figure 10f), demonstrating that microfluidic-based encapsulation in PEG-4MAL 
has no deleterious effects on human islet function or viability, and that mass 







Figure 10. PEG-4MAL microgels exhibit selective permeability to biomolecules 
and retain viability and function of encapsulated cells. (a) Release kinetics for 




demonstrate selective permeability. IgG was released from microgels slowly and 
incompletely. Conversely, glucose and insulin were rapidly released, indicating 
that mass transport of these smaller, function-preserving molecules is not grossly 
limited. (b) IgG was encapsulated in PEG-4MAL prepared from macromers of 10 
kDa or 20 kDa, and the tighter network structure generated with smaller 
macromer decreased permeability of microgel to IgG. (c) Human islets maintain 
high viability in culture after encapsulation. On days 1, 2, 5, and 8 after 
microencapsulation, viability of human pancreatic islets was imaged (c) (scale 
bars = 200µm) and quantified (d) using fluorescent area ratios between TOTO-3 
iodide (dead, purple) and calcein AM (live, green). (e) Human MSCs were 
encapsulated in microgels of various sizes (scale bars = 100 µm), and viability of 
hMSCs encapsulated in 400 µm microgels was quantified for 7 days post 
encapsulation. (f) No significant loss in viability was noted for hMSCs. (g) A 
glucose-stimulated insulin secretion assay, performed one day after human islet 
encapsulation, shows no significant difference between bare and encapsulated 
islets, demonstrating no functional losses in microencapsulated cells.  
The high potential of synthetic hydrogel microencapsulation for cell and 
protein therapeutics has been limited by the lack of synthetic polymer systems 
with tunable capsule size, cytocompatible crosslinking reactions, rapid 
crosslinking rates, adequate biomolecule permeability, and ease of 
functionalization with bioactive molecules (e.g., adhesive peptides). Using a 
synthetic hydrogel system with tunable network and crosslinking characteristics 




robust strategy for microencapsulation of cells in which we can control capsule 
size and local cellular microenvironment. Additionally, microgel network structure 
can be tuned to optimize permeability of the capsule to molecules of various 
sizes. We have demonstrated proof of concept with two different clinically 
relevant human cell types, but the versatility of this strategy will allow it to be 
tailored to fit diverse engineering applications. 
 
2.3 Experimental Section 
2.3.1 Microfluidic device preparation 
PDMS microfluidic flow focusing devices were cast using soft lithography from 
silicon and SU8 masters that were fabricated by the Stanford Microfluidics 
Foundry. Devices with 300 µm nozzles were bonded directly to glass slides after 
treatment with air plasma. 600 µm nozzle devices were manufactured by first 
bonding mirror-image PDMS channels, each with 300 µm depth, together to 
create a channel with 600 µm depth. 
2.3.2 PEG-4MAL microgel formation and particle encapsulation 
 Flow-focusing microfluidic geometry was utilized to form polymer droplets. Both 
shielding and crosslinker phases consisted of light mineral oil (Sigma) with 2% 
SPAN80 (Sigma). The crosslinker phase also contained an emulsion, at a ratio of 
1:15, of 20 mg/mL dithiothreitol (DTT) (Sigma) in PBS. A co-flowing shielding 
phase protected the macromer solution – a 5% PEG-4MAL (10 kDa or 20 kDa, 
Laysan Bio) solution containing molecules or cells to be encapsulated – from the 




rapidly diffused into macromer droplets, forming crosslinked microgels. To 
functionalize hydrogel with GRGDSPC (‘RGD’, AAPPTec), macromer was 
reacted for 20 minutes before encapsulation with 2.0 mM RGD in buffer solution 
containing 4 mM triethanolamine (Sigma). After formation, microgels were 
washed 5 times by centrifugation to remove mineral oil and excess DTT. 
2.3.3 Microgel size control 
To characterize the relationship between microgel size and the various 
macromer solution and continuous phase flow rates, hydrogel droplets were 
generated using computer-controlled syringe pumps, and were measured while 
still in the microfluidic chip. Harvard Apparatus Elite syringe pumps were 
computer controlled using FlowControl software to pump inlet solutions at various 
flow rates. Video was recorded during droplet generation using a Hammamatsu 
ORCA-ERA 1394 camera connected to a Nikon TE300 microscope. Droplet 
diameter was measured using ImageJ analysis software. The coefficient of 
variation (CV) was calculated for each flow rate combination by dividing the 
standard deviation of the sample by its mean. At least 30 microgels were 
measured for each flow rate combination. 
2.3.4 Protein encapsulation and release 
AlexaFluor488-labeled IgG (goat anti-rabbit IgG, Life Technologies), bovine 
serum albumin-AlexaFluor488 conjugate (Life Technologies), 2-NBD-glucose 
(Life Technologies) or insulin (Sigma) tagged with AlexaFluor488 was dissolved 




by macromer droplet gelation. To prevent proteins from being crosslinked by the 
macromer, thiols were capped using aminoethylate reagent (Thermo Scientific) 
according to product instructions. Particles were washed and resuspended in 
PBS and divided into 5 replicates containing 2 mL total volume. 50 µL samples 
were taken of supernatant alone, as well as of supernatant containing well-
mixed, protein-laden microgels. These samples were placed in a 96 well plate, 
and their fluorescent intensity was measured using a Perkin Elmer HTS 7000 
plate reader. To generate release curves, supernatant samples were collected 
over the course of 3 days, and their fluorescent intensity was measured. Protein 
release was normalized by setting fluorescent intensity of the supernatant alone 
correspond to 0% protein released, and fluorescent intensity of the 
buffer/microgel mixture correspond to 100% protein released. This data was 
plotted using GraphPad Prism, and exponential best fit curves were calculated 
from normalized data. 
2.3.5 Human MSC encapsulation and viability assay 
Passage 3 hMSCs (Texas A&M Health Science Center College of Medicine) 
were trypsinized and washed 3 times with PBS before being suspended in RGD-
functionalized macromer solution (5% wt macromer) at a concentration of 5 x 106 
cells/mL. Generation and subsequent gelation of cell-laden macromer solution 
droplets, using a microfluidic device with a 300 µm nozzle, resulted in 
microencapsulated hMSCs. These cells were maintained under static culture 
conditions in chemically defined MSC media (Lonza) for 7 days, with media 




removed from culture, stained with Calcein AM and TOTO-3 iodide (Life 
Technologies) for 15 minutes, washed, and resuspended in fresh media. At least 
200 cells were imaged each day using a Nikon Eclipse Ti microscope, and their 
viabilities were assessed based on fluorescent signal. ANOVA analysis was 
performed using GraphPad Prism software. The percent viability was calculated 
by taking the ratio of live cells to total cells. Viability data was plotted using 
GraphPad Prism. ANOVA analysis between the groups found no significant 
difference in viability, and a student’s t-test between days 1 and 7 also found no 
significant difference in viability. 
2.3.6 Human islet encapsulation and in vitro characterization 
Human pancreatic islets (PRODO Laboratories and the Integrated Islet 
Distribution Program) were suspended at a concentration of 2 x 104 IEQ/mL in 
culture media containing 5% (w/v) macromer. A microfluidic device with a 600 µm 
nozzle was used for droplet generation and subsequent crosslinking of the 
macromer solution, resulting in microencapsulated islets. After 
microencapsulation, islets were washed 5 times with media (PRODO labs 
PIM(S)), placed in fresh media, and allowed to recover overnight. On days 1, 2, 
5, and 8 after encapsulation, islets were stained with Calcein AM and TOTO-3 
iodide (Life Technologies) for 15 minutes, washed, and resuspended in fresh 
media. At least 74 islets were imaged each day using a Nikon Eclipse Ti 
microscope, and their viabilities were assessed based on fluorescent signal. For 
each islet, dead cell area to total islet area was computed, and this fraction was 




using GraphPad Prism software, and no significant difference in viability was 
found. On day 1 following encapsulation, a glucose-stimulated insulin secretion 
assay was performed. Islets were washed and were equilibrated using 1.67 mM 
glucose in Hanks Buffered Salt Solution for 30 minutes. Two groups, containing 5 
replicates of approximately 10 islets each, were collected from both 
microencapsulated and bare islets. One group from each treatment was 
incubated with high (16.7 mM) glucose HBSS, and the other group was 
incubated with low (1.67 mM) glucose HBSS for one hour. Supernatant from 
each sample was collected, and insulin content was quantified using human 
insulin ELISA (Sigma). DNA from each sample was then quantified using a 
Quant-iT PicoGreen kit (Invitrogen). Insulin secretion was normalized to DNA 
content for each well. The Stimulation Index for each replicate was calculated by 
taking the ratio of normalized high glucose insulin secretion to normalized low 
glucose insulin secretion (n=5). Groups were compared using a student’s t-test in 
GraphPad Prism. Human islets and MSCs were obtained by third party 







CHAPTER 3: TRANSPLANTATION OF MICROENCAPSULATED ISLETS IN 
PEG-4MAL HYDROGELS WITH OPTIMIZED CELL-MATRIX INTERACTIONS 





Encapsulation of islets in alginate hydrogel microspheres (microgels) can provide a 
sufficient immuno-isolation barrier to mitigate allogeneic rejection when delivered 
intraperitoneally (IP) to diabetic recipients. However, due to their fabrication method, 
alginate microgels are large relative to islets and the IP space has low vascular density, 
so diffusional limitations contribute to gradual graft destruction. Additionally alginate 
does not allow for recapitulation of native islet microenvironment through adhesive 
signaling. We previously developed a microfluidic platform for the size-controlled 
microencapsulation of islets in 4-arm poly(ethylene glycol) terminated with maleimides 
(PEG-4MAL), which is a hydrogel can be readily functionalized with thiolated bioactive 
molecules.  Here, we optimize the composition of PEG-4MAL hydrogels to support islet 
function in vitro, and compare the ability of PEG-4MAL and alginate microencapsulated 
islets to support islet health in vivo. 
3.2 Introduction 
 
Islet transplantation can restore glycemic control in patients with Type 1 diabetes. 
However, transplantation of islets from multiple donors is required to restore 




tissue, and islet grafts are prone to gradual destruction due to allo- and auto- 
immune reactivity, even with improved immuno-suppression regimes [47]. The 
current clinical standard for islet transplantation involves intrahepatic infusion of 
islets, which contributes even further to graft destruction by exposing directly to 
host blood and thereby to  instant blood-mediated inflammatory reaction (IBMIR) 
instigated by platelet and complement activation, resulting in immediate loss of 
50-60% of transplanted cells [51, 53]. Because this transplantation strategy 
requires long-term immunosuppression and results in islet destruction, significant 
efforts have been exerted to identify alternative delivery strategies.  
Encapsulation of islets in alginate microspheres (microgels) before 
transplantation into diabetic recipients can establish an adequate immuno-
isolation barrier to mitigate allogeneic rejection. However these microgels are 
typically large compared to islet size due to limitations electrostatic droplet 
extrusion with alginate, and therefore constitute a significant diffusional barrier—
not only to immune cells, but also to insulin, glucose, oxygen, and other 
molecules critical to cellular function. Furthermore, alginate is not easily modified 
for presentation of bioactive molecules, and so cannot recapitulate important 
aspect of the native islet microenvironment such cell adhesion binding sites, 
which have been shown to be important for islet survival and function. The 
synthetic hydrogel PEG-4MAL (4 arm polyethylene glycol terminated with 
maleimides) can be easily modified with thiolated bioactive molecules, allowing 
precise control of islet microenvironment, and has tunable permeability. 




applications. We have developed a microfluidic device for the size controlled 
microencapsulation of islets in PEG-4MAL microgels that simultaneously enables 
reduction in microgel diameter and recapitulation of adhesive signaling in the islet 
microenvironment[146], but microgel composition has not been optimized. 
Islet encapsulated in alginate microgels are usually transplanted into the IP 
space, which abrogates IBMIR mediated islet loss, but this site provides poor 
access of islets to host circulation. Rapid transport of oxygen, insulin, and 
glucose between transplanted islets and host circulation is required to maintain 
effective glycemic control. To enable this rapid transport, islets must be 
immobilized within a confined location near a dense vascular bed. We have 
previously developed a vasculogenic PEG-4MAL hydrogel that releases VEGF 
as it is degraded by invading cells, resulting in increased vascularization and 
function of transplanted allogeneic islets delivered to the small bowel mesentery 
(SBM)[63]. We have since identified a transplant sites that results in better 
vascularization and function than the SBM--the epididymal fat pad (EFP), a 
highly vascularized membranous tissue that is the murine equivalent of the 
human omentum[publication under review]. While immuno-isolation precludes 
direct vascularization of islets, the diffusional barrier between islets and host 
circulation can be minimized by decreasing encapsulating microgel diameter and 
simultaneously instigating new vascularization around microgels. 
Here, we optimized PEG-4MAL hydrogel composition for supporting islet health 




crosslinkers in vitro. Subsequently, we compared the ability of single donor islet 
mass to restore euglycemia in syngeneic recipients, when islets were 
unencapsulated, or were microencapsulated using optimized PEG-4MAL or 
alginate. Microencapsulated islets are compared in two different transplant sites, 
the EFP and IP space. Islets microencapsulated in optimized PEG-4MAL 
restored glycemic control better than islets microencapsulated in alginate and 
equally as well as unencapsulated islets when delivered to epididymal fat pads in 
diabetic syngeneic mice within bulk vasculogenic hydrogels. Lectin staining of 
functional vasculature confirmed that microencapsulated islets were not directly 
vascularized, but that vessels grew in close proximity to microgels, which 
supported islet graft function. 
 
3.3 Experimental 
Animals. Animal experiments were performed with the approval of the Georgia 
Tech Animal Care and Use Committee with veterinary supervision and within the 
guidelines of the Guide for the Care and Use of Laboratory Animals. In syngeneic 
studies, C57BL/6J male mice (10-14 weeks) were used as recipients and 
diabetes was induced by single dose streptozotocin i.p. injection (200 mg/kg) at 
pre-operative day 5. C57BL/6J female mice (10-14 weeks) were used as islet 
donors in transplant studies and for microgel in vitro characterization. Lewis rats 




Islet isolation. Islets were isolated by pancreatic perfusion with Liberase TL 
(Roche), 10 min of digestion at 37⁰C with gentle shaking, and ultra-pure (80-
90%) islet separation from acinar using standard Ficoll gradients (Mercodia: 
1.108, 1.096, 1.069, 1.037). Islets were counted using the standard islet 
equivalent method and dithizone staining. Islets were cultured in CMRL-1066 
complete medium (0.1 g/L L-glutamine, 25mM HEPES, 1% Pen/Strep, 10% 
FBS). 
Synthetic hydrogel optimization. To optimize hydrogel composition for islet 
delivery, a series of experiments was performed in which islets were bulk 
encapsulated in 50µL hydrogel constructs with varied chemistry and were 
cultured for 6 or 7 days before islet health and function were characterized. All 
synthetic gels consisted of 6% (w/v) PEG-4MAL (Laysan Bio) functionalized with 
2mM ligand density for all adhesive ligands tested. These hydrogels were 
crosslinked with varied dithiol molecules between experiments. Groups labelled 
‘nondegradable’ are crosslinked with entirely DTT (Sigma) or PEG dithiol (PEG-
DT, 226Da, Sigma). Groups labelled ‘degradable’ contain ½ nondegradable 
crosslinks (as specified per experiment) and ½ degradable crosslinks supplied by 
the peptide GCRDVPMSMRGGDRCG (VPM), which can be cleaved by MMPs. 
Bulk alginate hydrogels were made by first suspending islets in 50µL 1.6% Ultra-
Pure Low Viscosity Mannuronic (UP-LVM) alginate (Novomatrix) dissolved in 
PBS -/- (Gibco). Alginate-islet mixture was pipetted into a silicone mold which 




10mM MOPS, 140mM D-Mannitol, 0.025% vol/vol Tween-20, pH 7.4 ) for 10 
minutes. After crosslinking, construct was washed in complete CMRL-1066 
medium twice before culture. After encapsulation, all islets were cultured in 
complete CMRL-1066 with media changes every 2 days. On day 6 or 7 after 
encapsulation, glucose stimulated insulin secretion was measured for all 
encapsulated islets.  
To test glucose stimulated insulin secretion (GSIS), islets were first equilibrated 
for 1 hour in low glucose (1.67mM) solution dissolved in DMEM containing 
1%BSA. After equilibration buffer was discarded, 800µL of the same solution was 
added to each sample and was removed after one hour. Subsequently, a high 
glucose (16.7mM) solution was added to islets for an hour to stimulate insulin 
secretion. After collecting buffer containing high glucose sample, low glucose 
buffer was added again for one hour and then was collected for analysis. Insulin 
from all collected buffer samples was quantified by ELISA. Glucose Stimulation 
Index was calculated as the ratio of insulin secreted during high glucose 
incubation to the insulin secreted during initial low glucose incubation, and acts 
as a measure of glucose responsiveness. 
Following GSIS, various staining and imaging protocols were used to 
characterize islet health. To image live and dead cells, islets were stained with 
calcein AM and TOTO-3 iodide, respectively (Thermo Fisher), and maximum 
intensity projections are shown for z-stacks of representative islets obtained on 




activation using CellEvent kit (Thermo Fisher) as a marker of apoptosis and are 
presented superimposed on transmitted light images. Some samples were 
imaged using TUNEL assay (Click-iT green, Thermo Fisher) for DNA 
fragmentation, a more definitive marker of apoptosis. DAPI was used to 
counterstain nuclei blue on all TUNEL samples. Phase microscopy images were 
captured on an EVOS XL cell imaging system. 
 PEG-4MAL microencapsulation. Islets were microencapsulated in PEG-4MAL 
using a scheme similar to one reported previously [146]. One day after isolation, 
islets were dispersed in 6% PEG-4MAL with 2mM RGD made in a buffer of 1 part 
OptiPrep density gradient (Sigma):4 parts PBS +/+ to reduce islet settling. 
Droplets were formed from this dispersion in Mineral Oil (Sigma) containing 2% 
Span80 (Sigma) utilizing flow focusing microfluidics, and  then droplets were 
crosslinked by a DTT emulsified into the mineral oil continuous phase (Figure 
11). After crosslinking, encapsulated islets were washed with complete CMRL 
1066 medium 4 times by centrifugation to remove mineral oil, and were 






Figure 11. This schematic illustrates microfluidic encapsulation of pancreatic 
islets in PEG-4MAL microgels, which support islet function and may function as 
immunoisolation barriers. 
Alginate microencapsulation. One day after isolation, islets were dispersed in 
1.6% Ultra-Pure Low Viscosity Mannuronic (UP-LVM) alginate (Novomatrix) 
dissolved in PBS -/- (Gibco). Alginate-islet mixture was extruded through a 0.5 
mm diameter needle into a 1.5% BaCl2-MOPS crosslinking solution (50 mM 
BaCl2, 10mM MOPS, 140mM D-Mannitol, 0.025% vol/vol Tween-20, pH 7.4 ) 
using an electrostatic droplet generator (Nisco Engineering, Zurich, Switzerland). 
Capsules were allowed to crosslink 10 minutes, washed 3 times with PBS -/-, 
and resuspended in complete CMRL-1066 medium for overnight culture. 
Islet viability in microgels.  Islet viability was assessed after 48 hours 
encapsulation or unmodified culture. Metabolic activity was assessed via Alamar 




results from unencapsulated islets. Islet health was also assessed by Live/Dead 
Imaging (Invitrogen; Live: Calcein, Dead: Toto-3-Iodide).  
Modified GSIS studies with microgels.  48 hours post encapsulation, islets 
were suspended in KREBs buffer (99mM NaCl2, 5mM KCl, 1.2mM KH2PO4, 1.2 
MgSO4, 2.6mM CaCl2, 26mM NaHCO3, and 0.2% BSA) for static incubation. 
Unmodified or encapsulated islets were exposed to sequential D-glucose 
challenge in 30 minute intervals (3.3 mM, 6.6 mM, 9 mM, 13.2 mM, 16mM, 13.2 
mM, 9mM, 6.6 mM, 3.3 mM) to evaluate insulin secretion and diffusional delays 
due to encapsulation. 1 mL buffer was collected at each interval for evaluation by 
insulin ELISA (Mercodia). Insulin secretion was normalized to aliquot DNA 
content by Picogreen DNA kit (Invitrogen). (n=3, 200IEQ/n) 
Intraperitoneal (IP) encapsulated islet delivery. PEG-4MAL or alginate 
microgels containing islets were delivered by pipette in sterile saline (500 uL) to 
the peritoneal cavity through a 1 cm midline incision through the peritoneum. 
Peritoneum was closed via sutures and skin secured via surgical staples. 
Transplant recipients were monitored for nonfasting blood glucose levels for 75-
120 days. Grafts were retrieved after euthanasia by a peritoneal flush with saline. 
Epididymal Fat Pad (EFP) islet transplant via vasculogenic hydrogel 
delivery vehicle. One day post-encapsulation, 500 IEQ unmodified or 
encapsulated islets were dispersed within vasculogenic hydrogels (50 uL) to form 
two equal volume gels (25 uL each) for delivery to two EFP per animal. Gels 




glycol (PEG)-maleimide monomer (20 kDa , Laysan Bio) was functionalized with 
1.0 mM RGD peptide and 10 µg/mL VEGF (where applicable) at 37º C for a 
minimum of 15 min in gel buffer (PBS, 25 mM HEPES (Cellgro)). A separate 
crosslinking solution of VPM peptide was prepared in gel buffer. The pH for all 
solutions was adjusted to 7.0-7.5. To generate gels, functional macromers were 
mixed with unmodified or encapsulated islets and rapidly mixed with VPM 
crosslinker on a sterile paraffin surface, and swelled in complete CMRL-1066 for 
a minimum of 30 minutes prior to transplant. Peptide sequences: VPM 
(GCRDVPMSMRGGDRCG); RGD (GRGDSPC).  
Mice were anesthetized with 2% isoflurane prior to surgery. A midline 
incision was made through the peritoneum and both EFPs exposed and spread 
on sterile gauze via manipulation with forceps and saline wash. One 25 uL islet-
containing vasculogenic construct was deposited on each EFP surface (total of 
~500 IEQ per recipient), and the EFP gently wrapped around the construct. To 
seal the EFP, a 30 uL gel (10% 10 kDa PEG, 1mM RGD, VPM crosslinker) was 
deposited on the surface of the enclosed EFP graft prior to gentle return to the IP 
space, peritoneal suturing, and surgical staples to secure the skin. Transplant 
recipients were monitored for nonfasting blood glucose levels for 75-120 days. 
For lectin perfusion at experimental endpoint, anesthetized mice were 
given an intravenous lectin injection (DyLight 488-labeled lectin, 200 µL, Vector 
Labs) and sacrificed after 15 min, the vasculature flushed with saline prior to graft 




glass slides prior to whole-mount imaging on a confocal microscope. Z-stacks of 
each sample were acquired. 
3.4 Results and Discussion 
 
3.4.1 Synthetic hydrogel optimization 
Because PEG-4MAL hydrogels can be covalently functionalized with bioactive 
molecules, encapsulated islet microenvironment can be controlled precisely. 
Recapitulation of some aspects of native islet microenvironment, such as 
adhesive cell-matrix interactions, could lead to improved islet health and function.  
A series of experiments were conducted in order to optimize gel composition for 
optimal islet function, testing effect of adhesive ligands as well as crosslinkers on 
function of rat islets encapsulated in bulk hydrogels. Preliminary studies to 
establish experimental parameters indicated that variability would be high and 
that islets should be cultured in hydrogels long enough for differences would 
become apparent. Islet viability was consistently impaired by day 7 post 
encapsulation, so this time point was selected for end point assays. 
In the first of these experiments, islets were encapsulated in PEG-4MAL 
hydrogels which had been functionalized with an array of ECM derived peptide 
sequences with reported adhesive function. Hydrogels in this experiment were 
crosslinked with ½ degradable VPM and ½ nondegradable DTT crosslinks. After 
7 days in culture, islets functionalized with all adhesive ligands had comparable 




scrambled, non-adhesive RDG which led to widespread cell death (Figure 12A). 
Cells imaged in these groups appeared to remain rounded, forming minimal 
adhesive interactions with surrounding hydrogel when contrasted with cells in 
hydrogels with the other adhesive peptides tested. All treatment groups had 
reduced viability compared to the unencapsulated control, but this could be due 
to the inability of dead cells to evacuate microgels.  Results of glucose stimulated 
insulin secretion (GSIS) show impaired glucose responsiveness (GSI<1) of islets 
encapsulated in RDG and YIGSR, consistent with reduced viability in these 
groups (Figure 12B,C). However, islets encapsulated in hydrogels containing 
AG73 were glucose responsive even though they had impaired viability and did 
not appear to form adhesive interactions. Islets encapsulated in hydrogels 
containing the peptides IKVAV, C16, and A2G10 appeared to form cell adhesive 
interactions, maintained acceptable viability until day 7, and maintained glucose 
responsiveness (GSI>1), producing similar levels of insulin in GSIS assay. 
Although these adhesive peptides supported islet function, none were as 
effective as RGD, which maintained islet performance at comparable levels to 
the unencapsulated islet control. Because of these findings, only the adhesive 
peptide RGD and the scrambled non-adhesive peptide RDG were used in 







Figure 12. Viability and functional data are shown for rat islets encapsulated in 
bulk hydrogel constructs containing various adhesive ligands, and cultured for 7 




adhesive demonstrate varied cell-matrix interactions and cell responses, as 
discussed in the text. (B,C) Support of glucose responsiveness and insulin 
secretion also varied between adhesive ligands, as seen by in raw insulin, as 
well as glucose stimulation index plots. Hydrogels functionalized with RGD 
supported the best glucose responsiveness and greatest magnitude of insulin 
secretion on high glucose stimulation, comparable to unencapsulated islets (n=4, 
150IEQ each). Hydrogels were crosslinked with ½ DTT (nondegradable) and ½ 
VPM (degradable peptide) crosslinks. 
 
RGD was identified as the best available adhesive peptide for supporting islet 
function; however, this experiment was performed using hydrogels containing 
protease degradable crosslinkers, because their increased gelation times 
facilitated handling. Hydrogels with degradable crosslinks eventually lose 
integrity, so hydrogels with only nondegradable crosslinks were investigated for 
use as effective long term immuno-isolation barriers, in a follow up experiment 
(Figure 13). For these experiments, DTT was utilized as the non-degradable 
crosslinker. Additionally, alginate bulk gels were included as a control, because 
alginate is the current standard for islet encapsulation. Imaging of cells stained to 
indicate live and dead cells, as well as samples stained for caspase 3/7 
activation revealed comparable health of islets in RGD functionalized degradable 
hydrogels (Figure 13A). Alginate islets stained to indicate live and dead cells 
looked as healthy as bare controls as well, but notable caspase 3/7 activation 




degradable gels functionalized with RDG and in nondegradable gels with either 
adhesive ligand had similar, somewhat reduced islet health compared to other 
groups. Response to glucose challenge was dysregulated in hydrogels 
functionalized with the scrambled nonadhesive peptide RDG, whichever 
crosslinker was used (Figure 13B,C). In contrast, RGD functionalized hydrogels 
supported glucose responsiveness with both crosslinkers, and islets in 
degradable, RGD functionalized hydrogels had insulin secretion and glucose 
responsiveness similar to unencapsulated islets. Islets encapsulated in alginate 
also had similar function to bare islets even though minimal cell-matrix 








Figure 13. Viability, apoptosis and functional data are shown for rat islets after 
being cultured for 7 days encapsulated in bulk PEG-4MAL hydrogels, which were 
functionalized with RGD or RDG (non-adhesive scrambled peptide), and 
crosslinked either entirely with DTT (nondegradable) or with ½ DTT and ½ VPM 
(degradable peptide). Bare (unencapsulated) and alginate bulk gel controls are 
also included for comparison. (A) Representative live/dead [stained with calcein 
AM (green) and TOTO-3 iodide (cyan), respectively], and apoptosis [CellEvent 
caspase 3,7]  images of islets encapsulated in each adhesive demonstrate varied 
cell-matrix interactions and cell responses. (B,C) Support of glucose 
responsiveness and insulin secretion also varied between adhesive ligands, as 
seen by in raw insulin, as well as glucose stimulation index plots. Degradable 
PEG-4MAL hydrogels functionalized with RGD and bulk alginate hydrogels both 
supported similar glucose stimulated insulin release similar to unencapsulated 
controls. RGD functionalized hydrogels with nondegradable crosslinks also 
supported glucose responsiveness at an impaired level. (n=4, 40IEQ each). 
 
Because experiments with islets tend to have high variability, this experiment 
was repeated a second time. Hydrogels with only nondegradable crosslinks were 
poorly formed due to inadequate mixing resulting from rapid gelation, and results 
from these groups are unreliable, but the entireties of data collected are 
presented in Figure 14. Qualitative assessment of cell-matrix interactions can be 
seen in images, but in most nondegradable samples, it was difficult to find many 




Hydrogels crosslinked with degradable crosslinks were well formed, and results 
obtained with these samples are consistent with the experiment from Figure 13. 
Hydrogels functionalized with nonadhesive peptide RDG did not support islet 
function, but those functionalized with RGD enhanced insulin secretion compared 
to unencapsulated islet controls. Islets encapsulated in alginate were also 
glucose responsive, but secreted less insulin than islets encapsulated in 
synthetic hydrogels with RGD. 
Impaired islet health and function were noted when nondegradable DTT 
crosslinks were exclusively used, as outlined in Figure 13. This potential DTT 
associated toxicity, along with the marked difficulty of casting uniform 
nondegradable hydrogels with DTT, motivated us to try using a different non-
degradable crosslinker, PEG dithiol (PEG-DT), which had slightly slower 
crosslinking kinetics compared to DTT. Therefore, rat islets were isolated and 
encapsulated in bulk gels with identical composition as described before, except 
with equimolar PEG-DT in place of DTT. Islets in RGD functionalized hydrogels 
containing degradable crosslinks had similar health to unencapsulated control 
islets as indicated by live/dead and caspase 3/7 activation and additionally 
confirmed by the addition of a TUNEL assay for DNA fragmentation (Figure 15A). 
The TUNEL assay stained cells green, and cells were counterstained with DAPI 
in blue, but no notable differences were seen by this metric for any samples. 
Islets encapsulated in hydrogels other than RGD functionalized degradable gels 
appeared to have impaired viability; especially those in RDG functionalized 




supported the highest GSI and greatest insulin secretion of any composition 
tested (Figure 15B,C). Alginate and nondegradable PEG-DT crosslinked PEG-
4MAL supported similar, slightly reduced function of encapsulated islets. This 
finding is consistent between both nondegradable crosslinkers tested, DTT and 
PEG-DT. It appears, then, that decreased islet function may be associated with 
the inability of cells to remodel their microenvironment, and is not the result of 
DTT specific toxicity.  
The series of experiments shown here was meant to optimize microgel 
composition for supporting microencapsulated islet function in immuno-isolation 
applications. Islet function is best supported in degradable RGD functionalized 
hydrogels, but degradable crosslinks would result in an eventual break down of 
the immuno-isolation barrier. PEG-4MAL hydrogels with nondegradable 
crosslinks persist for months in vivo, and, when functionalized with RGD, can 
support islet function at similar levels to alginate in vitro. Because relative islet 
function did not improve notably when PEG-DT was used rather than DTT, DTT 
was selected as the nondegradable crosslinker for subsequent studies. A 
microfluidic scheme has been established for the encapsulation of islets in DTT 
crosslinked PEG-4MAL microgels, and permeability of these microgels appears 








Figure 14. Viability, apoptosis and functional data are shown along with phase 
contrast images for rat islets after being cultured for 6 days encapsulated in bulk 
PEG-4MAL hydrogels, which were functionalized with RGD or RDG (non-
adhesive scrambled peptide), and crosslinked either entirely with DTT 
(nondegradable) or with ½ DTT and ½ VPM (degradable peptide). Bare 
(unencapsulated) and alginate bulk gel controls are also included for comparison. 
(A) Representative phase contrast microscopy, live/dead [stained with calcein 
AM (green) and TOTO-3 iodide (cyan), respectively], and apoptosis [CellEvent 
caspase 3,7]  images of islets encapsulated in each adhesive demonstrate varied 
cell-matrix interactions and cell responses. (B,C) Support of glucose 
responsiveness and insulin secretion also varied between adhesive ligands, as 
seen by in raw insulin, as well as glucose stimulation index plots. Degradable 
PEG-4MAL hydrogels functionalized with RGD supported glucose stimulated 
insulin release similar to unencapsulated controls. Bulk alginate hydrogels also 








Figure 15. Viability, apoptosis and functional data are shown for rat islets after 
being cultured for 6 days encapsulated in bulk PEG-4MAL hydrogels, which were 
functionalized with RGD or RDG (non-adhesive scrambled peptide), and 
crosslinked either entirely with PEG-dithiol (PEG-DT) (nondegradable) or with ½ 
PEG-DT and ½ VPM (degradable peptide). Notably, the nondegradable 
crosslinker used is not DTT as used in previous experiments presented. Bare 
(unencapsulated) and alginate bulk gel controls are also included for comparison. 
(A) Representative live/dead images of islets which had been stained with 
calcein AM (green) and TOTO-3 iodide (cyan) are shown, along with images 
showing 2 markers of apoptosis: caspase 3,7 activation (CellEvent, green on 
transmitted light image) and DNA fragmentation (TUNEL, green and DAPI, blue). 
(B,C) Bulk alginate hydrogels and PEG-4MAL gels functionalized with RGD 
supported similar islet glucose stimulated insulin secretion, whether degradable 
peptide crosslinks were included or not when PEG-DT was used as the non-
degradable component of crosslinker. All groups were glucose responsive 
(GSI>1) on day 6 after encapsulation, but islets in hydrogels functionalized with 
non-adhesive RDG had notably impaired function. Unencapsulated islet controls 
had improved glucose responsiveness and insulin secretion compared to any 








3.4.2 Microgel encapsulated islet characterization 
 
Islets were encapsulated in PEG-4MAL microgels with chemical compositions 
identified in preliminary experiments (2mM RGD, DTT crosslinked), using a flow 
focusing microfluidic device that was previously reported [146]. 48 hours after 
encapsulation, islet viability was compared with unencapsulated control islets 
using Alamar Blue (Figure 16A) or live/dead imaging with calcein AM (green) and 
TOTO-3 iodide (magenta) (Figure 16C,D). In both comparisons, some minimal 
reduction in viability was noted in microencapsulated islets.  Also 48 hours after 
encapsulation, kinetics of islet glucose responsiveness were roughly 
characterized with a modified GSIS experiment. In this experiment, buffer was 
exchanged every 30 minutes with varying glucose concentration, so any gross 
impairment of insulin diffusion would manifest as lag time in insulin response.  No 
major lags in insulin release were seen in microencapsulated islets, and glucose 
responsiveness was at least as good as in unencapsulated control islets (Figure 
16B). Taken together, these results indicate that PEG-4MAL microgels 
functionalized with 2mM RGD and crosslinked with DTT can support 
encapsulated islet viability and function for 48 hours at comparable levels to 







Figure 16. Islets microencapsulated in PEG-4MAL microgels, functionalized with 
RGD, maintain their viability and function. (A) Islet viability is not significantly 
reduced by encapsulation as assessed by Alamar Blue. (B) Islets in PEG 
microgels increase insulin secretion in response to glucose fluctuations with no 
major capsule associated lag time. 
3.4.3 In vivo function of microencapsulated islets 
 
Enhancing vascularization of transplanted islets drastically improves their 




simultaneously quicken immune rejection of transplants when immunogenicity is 
a concern. Immuno-isolation and enhancement of direct islet vascularization are 
inherently incompatible strategies. However, by decreasing microgel diameter 
and increasing local vascular density, diffusional lag times caused by immuno-
isolating barriers can be minimized. Vasculogenic PEG-4MAL hydrogels that 
release VEGF on demand can enhance local vascular density at transplanted 
islets, resulting in improved blood glucose control in a syngeneic murine model of 
diabetes [63]. Since effective immuno-isolation eliminates direct islet 
vascularization, we tested whether increasing overall graft vascular supply 
enhanced function of microencapsulated islets by transplanting 
microencapsulated islets to diabetic recipients using two different transplant 
sites, the intraperitoneal (IP) cavity, and the epididymal fat pad (EFP). The IP 
space has been the most common site of transplantation for microencapsulated 
islets, but this site has a poor vascular supply. Conversely, the EFP is highly 
vascularized and microencapsulated islets were delivered to this site in 
vasculogenic degradable hydrogels, which further improved proximity of 
microencapsulated islets to host circulation. Islets microencapsulated in either 
nondegradable PEG-4MAL or the current standard material, alginate, were 
transplanted to each site in chemically diabetic mice, so the ability of these 
materials to support in vivo islet function could be compared. Islets which were 
not microencapsulated were also delivered to the EFP in vasculogenic bulk 
hydrogels as a control. A minimal islet mass of 500IEQ was transplanted per 




mass does not always restore euglycemia, but it makes differences in graft 
function more obvious than in transplants with higher islet loading. 
Results of transplant experiment are summarized in a persistence graph of 
diabetes in islet recipients (Figure 17A). Recipients were no longer considered 
diabetic when blood glucose stably dropped below 250 mg/dL. Between 20 and 
55 days post transplantation, 5/7 recipients receiving PEG-4MAL 
microencapsulated islets delivered to the EFP in vasculogenic hydrogels became 
stably euglycemic. Bare islets that were delivered to the EFP in a vasculogenic 
bulk gel restored euglycemia at similar rate and extent to PEG-4MAL 
microencapsulated islets, suggesting that nondegradable PEG-4MAL 
microencapsulation does not impair islet function in vivo. Loss of glycemic control 
upon explant of functional EFP grafts (marked by arrows near day 100), 
confirmed that euglycemia was maintained by islet graft, and was not due to 
recovered host function. Conversely, alginate microencapsulated islets delivered 
to the EFP in vasculogenic hydrogels did not restore euglycemia within 100 days 
for any of 5 recipients. This could be attributable to increased mass transport 
limitations introduced by larger alginate microgels, which could instigate hypoxic 
cell death. All diabetic mice receiving alginate microencapsulated islets in their IP 
cavity show rapid, promising recovery of glycemic control, but subsequent, 
gradual reduction of graft function was evidenced by increasing fluctuations in 
daily blood glucose measurements (Figure 17B). This gradual reduction of 
function may also be due to the increased diffusional barrier associated with 




cell death. PEG-4MAL microgels did not support islet function in the IP cavity, 





Figure 17.  In vivo functional performance of islets microencapsulated using 
either PEG-4MAL and microfluidic techniques, or alginate and electrostatic 
droplet extrusion. Data are shown for two separate transplant sites. (A) 
Persistence of diabetes over after transplantation is summarized for syngeneic, 
diabetic murine recipients.  (B) Daily blood glucose measurements used for 
production of summary plot are plotted for individual murine recipients. Islets 
transplanted to the IP space within alginate microgels reversed diabetes more 
rapidly than any other treatment, but resulted in unstable reversal of diabetes 
when compared with islets transplanted in microgels to the epididymal fat pad. 
3.4.4 Vascularization of microencapsulated islets 
Islets transplanted to the EFP were delivered in a vasculogenic bulk hydrogel 
that served as a substrate for invasion by host vasculature, and released 
bioactive VEGF as it was degraded. To assess the extent of vascularization, we 
labelled vasculature by perfusion with lectin in recipients of functional EFP grafts 
at the experimental end point. Lectin stained EFPs were explanted and functional 
blood vessels were fluorescently imaged with confocal microscopy. 
Representative images showing of ingrowth of host vasculature (green) 
superimposed on transmitted light photos are presented in Figure 18. Islets that 
were not microencapsulated were highly vascularized and were integrated into 
host vasculature. Islets microencapsulated in PEG-4MAL or alginate did not 
integrate with host vasculature because nondegradable microgels prevented 
invasion of host tissue. New host vasculature was often observed in close 




hydrogels (Figure 18). Because a dense vascular bed penetrated into packed 
microgels, decreasing microgel diameter reduced the distance required for 
diffusion between transplanted islets and host circulation. PEG-4MAL microgels 
had reduced diameter compared to alginate microgels, and the closer proximity 
of islets to host vasculature may partially explain improved functional 






Figure 18. Functional vasculature labelled with lectin in green is show 
superimposed over transmitted light images, for islets transplanted to the EFP 
within bulk vasculogenic VEGF hydrogels. Islets were transplanted in bulk gel 
only, or were first microencapsulated in PEG-4MAL or alginate. Bare islets 




blood vessels grow up to microcapsules but could not penetrate them. Smaller 
PEG-4MAL microgels had decreased distance of diffusion between islets and 
host circulation compared to larger alginate microgels. (Scale bar = 200µm) 
3.5 Conclusions 
 
Permeability of synthetic hydrogels can be tuned, similarly to alginate, for 
immuno-isolation applications, but synthetic hydrogels also enable simultaneous 
control of microencapsulated islet microenvironment, which is not easily 
accomplished with alginate. Therefore, six different peptide sequences were 
tested in PEG-4MAL hydrogels for their abilities to support islet health and 
function.  RGD was determined to support the best islet function, and the effect 
of crosslinker on encapsulated islets was investigated in RGD functionalized 
hydrogels. Hydrogels with non-degradable crosslinks supported slightly impaired 
function compared to hydrogels containing degradable crosslinks, whether DTT 
or PEG-DT were used as nondegradable crosslinking components. Although 
degradable hydrogels supported better islet function, their immuno-isolation 
potential is dubious. Therefore, non-degradable DTT crosslinked PEG-4MAL 
hydrogels were selected for further investigation, since they are more promising 
for immunoisolation and support similar islet function to alginate. 
Enhancing vascularization of islets improves their function in syngeneic diabetic 
recipients, but direct vascularization cannot occur when effective immuno-




encapsulate islets in PEG-4MAL microgels with diameters between 200-400µm, 
significantly smaller than typical alginate microgels produced by electrostatic 
extrusion which have diameters between 600-800µm. Islets microencapsulated 
in PEG-4MAL microgels with 2mM RGD and crosslinked with DTT showed only 
minimal reduction in viability and function after 48 hours when compared to 
unencapsulated controls, and did not show significant lag times in glucose 
responsiveness due to limited mass transport through microgels. 
Our delivery system for islets in vivo, was further optimized by transplanting 
PEG-4MAL microencapsulated to the EFP within vasculogenic bulk hydrogels, 
which secrete VEGF as they degrade, prompting dense vascular ingrowth. This 
strategy is preferred to typical IP delivery of microencapsulated islets, because it 
improves the proximity of islets to host circulation and allows for graft retrieval. 
Islets delivered with this 2 layered PEG-4MAL delivery system are capable of 
restoring euglycemia at comparable rates and extents to bare islets delivered in 
vasculogenic hydrogels, but alginate microencapsulated islets have impaired 
function in the EFP, even when delivered in vasculogenic hydrogels. Because of 
the reduced size of PEG-4MAL microgels compared to extruded alginate 
microgels, induced vasculature grows closer to encapsulated islets, minimizing 
the mass transport limitations resulting from microencapsulation. This difference 
in mass transport limitations could explain the functional differences noted 
between groups, although differences in material composition may also 
contribute. Whatever the cause, islets in PEG-4MAL microgels delivered to the 
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4.1 Abstract 
 
Islet transplantation is a promising therapy for type 1 diabetes. However, 
chronic immunosuppression to control rejection of allogeneic islets induces 
morbidities and impairs islet function. T-effector cells are responsible for islet 
allograft rejection and express Fas death receptor following activation, becoming 
sensitive to Fas-mediated apoptosis. Here, we report that localized 
immunomodulation using microgels presenting an apoptotic form of Fas ligand 
(SA-FasL) results in prolonged survival of allogeneic islet grafts in diabetic mice. 
A short course of rapamycin treatment boosted the immunomodulatory efficacy 
of SA-FasL-microgels, resulting in acceptance and function of all allografts over 
200 days. Survivors generated normal systemic responses to donor antigens, 




regulatory cells in the graft and draining lymph nodes. Deletion of T-regulatory 
cells resulted in acute rejection of established islet allografts.  This localized 
immunomodulatory biomaterial-enabled approach may provide an alternative to 
chronic immunosuppression for clinical islet transplantation. 
4.2 Main Text 
Type 1 diabetes (T1D) is an autoimmune disease characterized by loss of 
insulin-producing β-cell mass, and thereby glycemic control, due to a coordinated 
immune response against β-cell specific antigens requiring CD4+ T cells [173-
175]. Restoration of β-cell mass through allogeneic islet transplantation is the 
current preferred clinical intervention to improve glycemic control [11, 13, 176]. 
However, longevity of allogeneic grafts is limited by host immune responses as 
well as secondary graft failure due to toxic effects of chronic immunosuppression 
required to control rejection [177, 178]. Pathogenic T effector (Teff) cells are the 
major culprit of islet allograft destruction [179, 180]. Therefore, a promising 
strategy to increase the functional longevity of islet allografts without the need for 
long-term immunosuppression comprises novel therapies that target Teff cells for 
elimination, mitigating their pathogenic function [181]. 
Upon activation, T cells upregulate Fas and become sensitive to FasL-
mediated apoptosis, a process that plays a critical role in activation-induced cell 
death (AICD) and tolerance to self-antigens [182]. Deficiency in Fas or FasL 
results in massive lymphoproliferation and autoimmune pathologies in rodents 




regulation [183].  Recognizing the immunomodulatory potential of this pathway, 
several groups have successfully used FasL gene therapy to mitigate allogeneic 
immune responses for graft acceptance in experimental animal models [184-
188]. Although these interventions show efficacy, the unknown safety profile of 
sustained ectopic expression of FasL in target tissues, as well as technical and 
regulatory challenges of gene therapy, limit their clinical potential. Additionally, 
FasL only contributes to AICD in its membrane-bound, oligomeric form [189]. 
Matrix metalloproteinases (MMP) can cleave FasL into an extracellular soluble 
form that inhibits apoptosis and acts as a chemoattractant for neutrophils, 
accelerating the destruction of allografts [190].  To use FasL as an effective 
immunomodulatory agent, we have previously reported the construction of a 
chimeric form of FasL with streptavidin (SA), SA-FasL, in which the extracellular 
domain of FasL, lacking MMP sensitive sites, was cloned C-terminal to SA [191]. 
This protein exists as tetramers and oligomers with robust apoptotic activity on 
Fas-expressing cells. Importantly, pancreatic islets, modified with biotin attached 
to the cell surface followed by engineering with SA-FasL, acquired an immune 
privileged status and survived indefinitely in the absence of chronic 
immunosuppression in an allogeneic transplant murine model [192].   
Here, we engineered a novel biomaterial for the sustained presentation of 
SA-FasL within the islet graft microenvironment, eliminating the need for islet 
modification, to establish a translatable, effective immunomodulatory strategy 
without chronic immunosuppression. Hydrogel microparticles (microgels) were 




macromers using microfluidics polymerization [146]. The PEG-4MAL platform 
enables stoichiometric, covalent incorporation of thiol-containing molecules, and 
provides improved crosslinking efficiency for formation of structurally defined 
hydrogels [143]. PEG-4MAL exhibits minimal toxicity in vivo, and it is rapidly 
excreted in the urine [63], important considerations for clinical applications. 
Biotinylated microgels were produced by reacting biotin-PEG-thiol with PEG-
4MAL macromer, and generating 150 µm diameter microgels crosslinked with 
dithiothreitol (DTT) via microfluidics polymerization (Figure 19A). The resulting 
microgels displayed covalently-tethered biotin capable of capturing SA with high 
affinity (Figure 19B). Moreover, biotin-specific capture of SA on microgels varied 
linearly with concentration of SA in the tethering solution up to a saturating 
concentration of 150 µg/mL (Figure 19C), demonstrating dose-dependent control 
of SA presentation on the microgel surface. As expected, capture of SA-FasL on 
biotinylated microgels obeyed a similar dose-dependent relationship (Figure 23). 
Importantly, display of SA-FasL on microgels induced dose-dependent apoptosis 
in A20 cells (Figure 19D), which are sensitive to FasL-mediated apoptosis. In 
contrast, direct covalent coupling of SA-FasL to the PEG-4MAL macromer 
eliminated SA-FasL apoptotic activity (Figure 24), demonstrating the importance 
of biotin immobilization for presentation of bioactive SA-FasL. These results 
show that SA-FasL tethered to biotinylated microgels retains potent apoptotic 
activity, and that the quantity of bioactive SA-FasL delivered can be easily 






Figure 19. Microgels for controlled presentation of immunomodulatory proteins. 
(A) Flow focusing microfluidics were used to generate biotinylated microgels from 
biotin-functionalized PEG-4MAL macromers. SA-FasL was immobilized on 
microgels and these immunomodulatory microgels were co-transplanted with 
islets under the kidney capsule of diabetic mice, inducing graft acceptance. (B,C) 
Biotinylated microgels capture and display SA in a dose-dependent manner until 
reaching saturation. (D) SA-FasL presented on microgels maintains bioactivity 





We next investigated the retention of SA-FasL presented on microgels in 
vivo. SA-FasL that had been labelled with a near-infrared fluorescent dye was 
immobilized on biotinylated microgels, which were implanted under the kidney 
capsule of mice. Longitudinal tracking of labelled SA-FasL was performed on an 
in vivo imaging system for 21 days. Images for fluorescent signal show 
concentrated signal localized to the area around the kidneys in mice receiving 
labelled SA-FasL-presenting microgels, whereas the fluorescent signal is diffuse 
for mice receiving labelled free SA-FasL without the microgel carrier (Figure 
20A). In mice receiving only labelled SA-FasL, without the microgel delivery 
vehicle, the protein was rapidly cleared from the transplant site, with a 60% 
reduction in signal by day 4 post-implantation and negligible signal by day 11 
after implantation (Figure 20B). In contrast, mice receiving SA-FasL-presenting 
microgels displayed significantly higher levels of SA-FasL over time with elevated 
levels comparable to day 0 signal at the site of implantation over 7 days post-
transplantation. Analysis of retention profiles showed significantly longer 
retention times for SA-FasL-presenting microgels compared to free SA-FasL (9.6 
± 2.8 days vs. 3.2 ± 1.3 days, p < 0.038). Furthermore, area-under-the-curve 
calculations demonstrated increased retention of SA-FasL for microgel-tethered 
vs. free protein (4.25 ± 0.82 vs. 2.07 ± 0.21, p < 0.034). We expect that this 
biomaterial strategy for extended SA-FasL delivery in graft sites significantly 
enhances the local effects while minimizing risks of systemic effects of this potent 






Figure 20. Microgels prolong SA-FasL retention in vivo. SA-FasL was labelled 
with a near-IR dye and implanted under the kidney capsule of mice and imaged 
in vivo. (A) Representative images show localization of SA-FasL to graft site 
when presented on microgels, in contrast to diffuse signal measured in animals 




treatment group. Images are not shown for days 18 and 21 because signal was 
negligible. (B) Quantification of in vivo fluorescence demonstrates that microgels 
presenting SA-FasL prolong protein retention compared to free SA-FasL 
(p<0.038; n=8). 
 
The immunomodulatory efficacy of microgels presenting SA-FasL was 
tested in an allogeneic islet transplantation setting. Unmodified allogeneic 
(BALB/c) islets were mixed with microgels, and the resulting mixture was 
transplanted under the kidney capsule of streptozotocin-diabetic C57BL/6 mice. 
Mice receiving unmodified islets and control biotinylated microgels acutely 
rejected all grafts [median survival time (MST) = 14.6 ± 1.7 days; Figure 21A).  
Islets co-transplanted with SA-FasL-engineered microgels had significantly 
prolonged survival (MST = 37.6 ± 9.0 days). The presentation of SA-FasL on 
both microgels and biotinylated islets further delayed rejection with four grafts 
rejecting within 59 days and one graft surviving for the 200-day observation 
period.  The improved performance of this group suggests a dose-dependent 
immunomodulatory effect for SA-FasL. This was confirmed in mice receiving 
microgels engineered with 10 times more SA-FasL protein which further 
improved graft survival as 2/5 unmodified islet grafts did not show signs of 
rejection by the 200-day experimental end-point (Figure 21A, B). Notably, all 
grafts (n=5) functioned and survived for the entire 200-day observation window in 
mice co-transplanted with unmodified islets and SA-FasL-presenting microgels 




initiated on day 0 post-transplantation for 15 doses; Figure 21A,Figure 25). 
Intraperitoneal glucose tolerance tests demonstrated equivalent function of these 
long-term grafts compared with naïve mice (Figure 21C). In marked contrast, the 
same protocol with rapamycin injections but without SA-FasL-engineered 
microgels resulted in acute rejection (MST = 20.6 ± 3.9 days) (Figure 21A). 
Taken together, these results show that simple co-transplantation of allogeneic 
islets and SA-FasL-engineered microgels restores long-term glycemic control 










Figure 21. Survival of allogeneic islet grafts co-transplanted with SA-FasL-
presenting microgels. (A) Islet graft survival. Biotinylated microgels were 
engineered with SA-FasL (1 µg protein/1000 microgels, unless otherwise noted) 
and co-transplanted with unmodified or SA-FasL-engineered BALB/c islets 
(500/transplant) under the kidney capsule of chemically diabetic C57BL/6 
recipients. Rapamycin was used at 0.2 mg/kg daily i.p. injection for 15 doses 
starting the day of transplantation in the indicated groups. Animals were 
monitored for blood glucose levels and two consecutive daily readings of ≥ 250 
mg/dL were considered to be diabetic (rejection).  (B) Immunostaining of a long-




SA-FasL showing insulin (red) and glucagon (green) positive cells as well as 
DNA (blue). (C) Intraperitoneal glucose tolerance test showing long-term islet 
grafts with normal function. (Data generated by Shirwan laboratory in 
collaboration with our group) 
 
Because of the localized nature of immunomodulation, we assessed the 
systemic response of graft recipients to donor antigens in an in vitro proliferation 
assay. Both CD4+ and CD8+ T cells from long-term (> 200 days) islet graft 
recipients treated with SA-FasL-engineered microgels showed proliferative 
responses to donor as well as third party antigens (Figure 22A).  The observed 
responses were at similar magnitudes to those obtained using T cells from 
rejecting mice receiving unmodified microgels plus rapamycin. This result 
indicates that mice receiving SA-FasL-engineered microgels maintain systemic 
immune competence, and that the protection afforded by SA-FasL-engineered 
microgels remains localized to the graft, as reported previously in two transplant 





Figure 22. Immune monitoring and the role of CD4+CD25+FoxP3+ Treg cells in 
islet graft acceptance. (A) Systemic response of long-term graft survivors to 
donor antigens. Splenocytes from the indicated groups were labeled with 
carboxyfluorescein succinimidyl ester (CFSE) and used as responders to 
irradiated BALB/c donor and C3H third party stimulators in an ex vivo mixed 







was assessed using antibodies to CD4 and CD8 molecules in flow cytometry and 
plotted as percent division for each cell population.  (B) Time course analysis of 
immune cell types.  Single cells prepared from the spleen, kidney, and kidney-
draining lymph nodes of the indicated groups on day 3 and 7 post-islet 
transplantation were stained with fluorescence-labelled antibodies to cell surface 
molecules that define CD4+ Teff (CD4+CD44hiCD62Llo), CD8+ Teff 
(CD8+CD44hiCD62Llo), and Treg (CD4+CD25+FoxP3+) populations and analyzed 
using flow cytometry. The ratios of Treg to CD4+ Teff and CD8+ Teff are plotted 
(mean ± SEM, *p < 0.05, **p < 0.005). (C) Depletion of Treg cells results in acute 
rejection of established islet grafts. C57BL/6.FoxP3EGFP/DTR mice (n=5) were 
transplanted with BALB/c islet grafts and SA-FasL-presenting microgels under 
transient cover of rapamycin (administered i.p. daily at 0.2 mg/kg for 15 doses). 
These mice were then injected i.p. with 50 µg/kg diphtheria toxin on day 50 post-
transplantation (arrow) to deplete Treg cells. (Data generated by Shirwan 
laboratory in collaboration with our group) 
 
 
To further elucidate the mechanism of graft acceptance, immune cell 
populations harvested from the spleen, graft draining lymph nodes (LNs), and the 
graft were analyzed using flow cytometry in a time-course study, with particular 
focus on Teff and T-regulatory (Treg) cells as targets of FasL-mediated 
immunomodulation.  We observed a trend towards an increased ratio of Treg to 




draining LNs (p < 0.05 for both Treg:Teff populations) in groups receiving SA-
FasL-engineered microgels and rapamycin compared to control groups receiving 
unmodified microgels alone or in combination with rapamycin (Figure 22B). Treg 
cells, similar to Teff cells, follow the inflammatory cues and infiltrate into rejecting 
grafts without a functional consequence [194, 195]. As such, we conducted a 
depletion study to directly assess the role of Treg cells in the observed graft 
acceptance in our model.  For these studies, BALB/c allogeneic islets were 
transplanted into transgenic C57BL/6 mice expressing simian diphtheria toxin 
receptor under the control of Foxp3. Chemically diabetic transgenic mice 
transplanted with allogeneic islets and SA-FasL-engineered microgels under the 
transient cover of rapamycin established graft acceptance, as seen previously in 
C57BL/6 recipients, with all mice maintaining graft function at day 50 post-
transplantation. Depletion of Treg cells by administration of DT on day 50 
resulted in rejection of all grafts by day 82 (Figure 22C, S3; MST = 72.2 ± 10.2 
days), demonstrating the dominant role of this cell type in graft acceptance.  
These results are consistent with the established role of FasL in 
physiological immune privilege for selected tissues, such as the anterior chamber 
of the eye and the testes [196-198]. The observed protection against rejection 
required Treg cells and was localized to the graft, as long-term recipients 
generated a normal systemic response to the donor antigens, implying immune 
privilege. This is consistent with a study demonstrating that primary myoblasts 
transfected to express FasL conferred immune privilege to co-transplanted 




allogeneic islets engineered to display SA-FasL protein on their surface under a 
short cover of rapamycin overcame rejection by inducing graft-localized tolerance 
and immune privilege, maintained by Treg cells [199].  
Engineering microgels with SA-FasL allows controlled loading, 
presentation, and retention of SA-FasL protein within the graft microenvironment 
for immunomodulation.  This is a unique advantage over gene therapy, because 
uncontrolled, continuous expression of FasL, which possesses pleiotropic 
functions and different modes of expression that may be differentially regulated 
by the target tissues (membrane bound or soluble), may have unintended 
consequences. Indeed, ectopic expression of FasL using gene therapy for 
immunomodulation in transplantation settings has resulted in mixed and 
opposing outcomes with some studies showing detrimental impact of FasL 
expression on graft survival [200]. The localized and sustained presentation of 
SA-FasL with robust apoptotic function using microgels overcomes complications 
associated with ectopic expression of wild-type FasL in target tissues using gene 
therapy. This localized immunomodulation concept also limits potential toxicities 
associated with agonistic antibodies against Fas for immunomodulation [201]. 
Lastly, SA-FasL-engineered microgels provide the flexibility of an off-the-shelf 
product for wider clinical applications, as these immunomodulatory materials can 
be prepared at the time of transplantation and simply co-mixed with islets for 
delivery without the need of encapsulating islets or manipulating islets to present 
proteins.  Further studies in large animal or humanized mouse models will be 






Microgel synthesis and characterization. A microgel precursor solution 
containing 5% w/v PEG-4MAL (20kDa, Laysan Bio) and 1.0 mM biotin-PEG-thiol 
(1 kDa, Nanocs) was reacted for 15 min in PBS. This precursor was dispersed 
into droplets and subsequently was crosslinked within mineral oil (Sigma) 
containing 2% SPAN80 (Sigma) and a 1:15 emulsion of 30 mg/mL dithiothreitol 
(Sigma) on a microfluidic chip, as described previously [146]. Control microgels 
which did not contain biotin-PEG-thiol were also synthesized using this protocol. 
After washing microgels 5 times by centrifugation in 1% bovine serum albumin 
(Sigma) in PBS, 104 microgels were incubated with varying concentrations of a 
streptavidin-AlexaFluor488 conjugate for 30 min in 500 µL PBS, and were 
washed 5 times by centrifugation to remove unbound SA. Microgels from each 
sample were placed in a 96-well plate and fluorescence was measured on a 
plate reader (Perkin Elmer HTS 7000). Biotin and control microgels were also 
synthesized with a covalently bound peptide (GRGDSPC)-AlexaFluor594 
conjugate for capsule visualization, and were fluorescently imaged to confirm 
biotin-specific SA immobilization. 
In vitro bioactivity. 104 microgels, with or without biotin, were co-incubated for 
30 min in 500 µL PBS with 1% bovine serum albumin containing varying 
concentrations of SA-FasL. Microgels were washed 8 times by centrifugation to 
remove unbound SA-FasL, and were incubated with 106 A20 cells in 1.0 mL 




(annexin V-APC and propidium iodide, BD Biosciences). Samples were analyzed 
by flow cytometry (Accuri C6 flow cytometer) and cells staining positive for either 
marker were considered apoptotic. 3 independent replicates of this experiment 
were performed. 
In vivo SA-FasL tracking. SA-FasL was labelled with AlexaFluor750 NHS Ester 
(Thermo Fisher), and free dye was removed by desalting in Zeba column (7k 
MWCO, Thermo Fisher) three times. 3.0 µg of labelled SA-FasL was immobilized 
onto 2000 biotin microgels by incubation for 30 minutes followed by 5 wash 
steps. Microgels presenting SA-FasL or free SA-FasL were implanted under the 
kidney capsule of C57Bl/6 recipients (n=8 mice/group), and signal intensity and 
distribution were monitored longitudinally using an IVIS SpectrumCT imaging 
system. Intensity measurements were normalized to day 0 values. Non-linear 
curve fits were performed in GraphPad Prism and retention time was compared 
using a t-test. Additionally, area under the curve was calculated for each group, 
and a Welch’s t-test was used to compare groups.  
Islet transplantation. BALB/c pancreatic islets were isolated using Liberase TL 
as a digestive enzyme (Roche Life Science) and purified by a Ficoll density 
gradient as previously published [191]. To biotinylated islets, overnight cultured 
islets were incubated in 5 µM EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific) 
for 30 min at room temperature, washed extensively with PBS to remove 
unbound biotin solution. Biotinylated islets and microgels were engineered with 
SA-FasL (~150 ng/500 islets and 1-10 µg/1000 microgels). Five hundred islets 




mg/dL) C57BL/6 recipients.  Selected groups were also treated i.p. with 
rapamycin at 0.2 mg/kg daily for 15 doses starting the day of transplantation. 
Unmodified BALB/c islets co-transplanted with unmodified PEG gels were used 
as controls. Animals were monitored for blood glucose and ≥ 250 mg/dL blood 
glucose levels for two consecutive daily measurements were considered 
rejected. 
Immune monitoring.  Spleen, kidney, and kidney draining lymph nodes were 
harvested from rejecting and long-term mice (> 200 days). Single cells were 
prepared from the spleen and lymph nodes by gentle mechanical dispersion and 
from islet harboring kidney by collagenase digestion. Cells were stained using 
antibodies to cell surface markers (Alexa 700-CD4 Ab, APC-Cy7-CD8 Ab, PE-
Cy7-CD25 Ab from Pharmingen, BD, and eFlour 450-CD44 Ab and PerCP-
Cy5.5-CD62L Ab from eBioscience). Intracellular FoxP3 staining was carried out 
on fixed/permeablized cells using FoxP3 Transcription Factor Staining Buffer set 
(eBioscience). Data was collected using BD LSR II and analyzed using Diva 
software. 
Proliferation assay. Splenocytes harvested from selected group of transplant 
recipients were labeled with CFSE and used as responders to irradiated (200 
cGy) splenocytes from donor or third party C3H mice in a standard in vitro 
proliferation assay [192].  After 4 days in culture, cells were stained with 
fluorescence-conjugated Abs against CD4 and CD8, and analyzed for CFSE 





Confocal Microscopy. After the observation period of 200 days, long-term islet 
bearing kidneys were snap frozen in OCT compound (Sakura Tissue-Tek) by 
submerging in methyl butane (Sigma) on dry ice. Tissues were cut in 10 µm-thick 
slices using a Bright OTF5000 cryomicrotome (Rose Scientific) and put on 
frosted slides for staining. Slides were fixed in 4% paraformaldehyde, incubated 
in 0.5% Triton X-100, and blocked in 0.1% bovine serum albumin, 5% goat 
serum, and rat anti-mouse CD16/CD32 (BD Pharmingen). Staining was 
performed using rabbit anti-glucagon mAb (Cell Signaling) and guinea pig anti-
insulin polyclonal antibody (Dako) as primary antibodies, followed by washing 
and staining with AlexaFluor-647-conjuaged goat anti-rabbit antibody (Life 
Technologies) and AlexaFluor-555-conjugated anti-guinea pig antibody 
(Invitrogen). Hoechst 33342 (Molecular Probes) was used to stain DNA.  
Fluorescent images were obtained using a Leica TCS SP5 confocal microscopy 












4.4 Supplementary Figures 
 
 
Figure 23. SA-FasL is tethered to biotinylated microgels in a dose-dependent 
manner. Biotinylated microgels (104) were suspended in 500 µL of SA-FasL or 
SA only solution at the concentrations indicated for 1 h. Microgels were then 
washed by centrifugation 10 times in 1% bovine serum albumin in PBS to 
remove unbound protein. Functionalized microgels were incubated with a 1:100 
dilution of fluorescently labelled anti-FasL antibody for 1 h, followed by 10 
washes by centrifugation. Washed microgels were placed in a 96 well plate and 
read on Perkin Elmer HTS 7000 plate reader, and background signal (empty 






Figure 24. Direct tethering of SA-FasL to PEG-4MAL macromer reduces 
bioactivity. Various doses of SA-FasL were reacted with 10 µL of 10% PEG-
4MAL macromer in solution for 1 h. Either untreated soluble SA-FasL or 
PEGylated SA-FasL was incubated with A20 cells overnight, and the number of 
apoptotic cells was determined by flow cytometry after staining with annexin V-






Figure 25. Blood glucose levels. Readings were taken on chemically diabetic 
C57BL/6 mice transplanted with microgels presenting SA-FasL (1 µg 
protein/1000 microgels) and naïve BALB/c islet grafts (500) under a short cover 
of rapamycin (administered i.p. daily at 0.2 mg/kg for 15 doses). Controls 
included mice subjected to the same regimen, except receiving microgels without 




CHAPTER 5: PARALLEL DROPLET MICROFLUIDICS FOR HIGH 







Cells can microencapsulated in synthetic hydrogel microspheres 
(microgels) using droplet microfluidics, but microfluidic devices with a single 
droplet generating geometry have limited throughput, especially as microgel 
diameter decreases. Here we demonstrate the microencapsulation of human 
mesenchymal stem cells (hMSCs) in small (< 100 µm diameter) microgels, 
utilizing parallel droplet generators on a two-layer elastomer device, which has 
600% increased throughput vs. single nozzle devices. Distribution of microgel 
diameters were compared between products of parallel vs single nozzle 
configurations for two different square nozzle widths, 35 µm and 100 µm. 
Microgels produced on parallel nozzles were equivalent to those produced on 
single nozzles, with no major increase in polydispersity noted. 
Microencapsulation of hMSCs was compared for parallel nozzle devices of each 
width. 35 µm wide nozzle devices could be operated at twice the cell 
concentration of 100 µm wide nozzle devices, but their volumetric throughput 




microgels were produced than predicted by the Poisson distribution. 100 µm wide 
nozzle devices produced microgels as predicted by the Poisson distribution. 
Microgel size was impacted by the addition of cells, increasing on 35 µm nozzle 
devices but decreasing on 100 µm nozzle devices. Polydispersity of microgels 
did not increase with the addition of cells for either nozzle width. Viability of 
hMSCs encapsulated on 100 µm wide nozzle devices was >90% after 
encapsulation, but cells encapsulated on 35 µm wide nozzle devices had 
reduced viability of ~70%, suggesting nozzle size-dependent damage to cells.   
5.2 Introduction 
Delivery of encapsulated proteins and cells in hydrogel microspheres, or 
microgels, has emerged as a promising therapeutic strategy for the treatment of 
disease[202]. Some synthetic polymers, especially those utilizing bio-orthogonal 
click chemistry, provide tuneable release rates of encapsulated proteins which 
can be tailored based on hydrolytic or enzymatic degradation of microgels[149, 
203]. These injectable microgels can be non-invasively implanted for extended 
local delivery of therapeutic proteins, such as growth factors and cytokines. 
Additionally, microgel delivery of proteins allows for ‘mosaic’ injections, in which 
multiple capsules with individually validated release profiles can be combined to 
provide more complex release profiles or multi-protein delivery. Encapsulation of 
cells in microgels provides several key benefits in transplantation settings. By 
controlling diffusivity properties of microgels, immune infiltration of transplanted 




maintained. Because potential sources of therapeutic cells are often allogeneic or 
xenogeneic, this protection mechanism has been extensively investigated for 
reduction required immunosuppression for transplant acceptance. Microgels can 
also function to immobilize cells at a desired location by entrapping them in gels, 
an important consideration since many cell therapies currently rely on systemic 
administration of cells. In addition to isolating transplanted cells from the host, 
synthetic microgels permit engineering of encapsulated cell microenvironment, 
including matrix stiffness and adhesive ligand interactions, which are known to 
influence encapsulated cell health and function. Bulk hydrogel constructs can 
provide these benefits as well, but the microgel form factor enables applications 
for which bulk gels are not well suited, such as injection. Additionally, thick 
polymer coatings are a barrier to nutrients and oxygen, so hypoxic death is 
frequently observed with in cells at high concentration in bulk gels, and even in 
large microgels [204]. Therefore, microgel size should be minimized in order to 
maximize transport of oxygen to encapsulated cells, and to enable novel, 
minimally invasive transplantation schemes. 
We have previously  developed a microfluidic droplet strategy for 
generating size-controlled crosslinked synthetic microgels based on 4 arm 
poly(ethylene) glycol (PEG-4MAL) macromers which are terminated with 
maleimides [146]. Maleimides efficiently react with free thiols to form covalent 
bonds, allowing any cysteine containing peptide or thiolated ligand to be tethered 
to microgels. This versatile chemistry enables local sustained presentation of 




therapeutic proteins when microgels are crosslinked with protease-sensitive 
crosslinks [203]. Crosslinking PEG-4MAL macromers can be accomplished with 
dithiol molecules and does not require free radical initiators, which are 
detrimental to encapsulated cell health [205]. Similar microfluidic schemes for 
producing microgels [166, 206, 207] and encapsulating cells [159, 208, 209] have 
recently been reported for widely varying applications, including wound healing, 
stem cell culture, and fundamental studies of cell biology.  
Microfluidics can provide precise control of size and polydispersity of 
droplets [210], and can be used to generate microgels with polymers that are not 
amenable to extrusion processing [101]. Minimization of microgel diameter 
maximizes diffusion of oxygen and nutrients to encapsulated cells, enables 
applications for which larger microgels are not suited (such as injection), and 
potentially reduces transplant graft volume. Unfortunately, volumetric throughput 
of macromer decreases with the cube of droplet diameter, so volumetric 
throughput can be severely limited when very small microgels are being 
produced. Furthermore, cells suspended at high concentrations tend to 
aggregate, which can lead to incomplete cell encapsulation as well as increased 
microgel diameters. Therefore, to minimize cell-laden microgel diameter, a low 
concentration cell suspension must be used, resulting in a higher percentage of 
empty microgels. Microgels containing cells can be purified by sorting, or can be 
selectively crosslinked [211], but encapsulating clinically relevant numbers of 
cells in these very small microgels is highly challenging. Long processing times 




faster cell microencapsulation rates are desirable for therapeutic efficacy, not just 
convenience. 
To maximize encapsulated cell production rate, both the concentration of 
cells in macromer and the volumetric throughput of macromer in microfluidic 
devices must be maximized. One way to increase flow rate of macromer in a 
microfluidic droplet generating device is to utilize a parallel flow focusing nozzle 
configuration. However, maintaining size control and low polydispersity of droplet 
diameter are very challenging when parallel nozzles are used, because coupled 
flows cause fluctuations to propagate between nozzles. Nonetheless, uniform 
droplet production has been shown on parallel droplet generators with a variety 
of configurations [212-216]. Parallel microfluidics have been used to produce 
microgels through light-initiated free-radical polymerization on single layer 
microfluidics, and the nature of crosstalk between parallel droplet generators has 
been studied in this context [217]. Furthermore, in an impressive display of 
microfluidic control, even uniform double emulsion polymerosomes were formed 
on parallel geometries [218, 219]. However, suspensions containing high density 
cell suspensions complicate fluid behaviour and may cause nonuniform 
distribution of fluid to focusing nozzles. Likely because of these hurdles, parallel 
droplet generators have not been utilized to date for suspension of cells in 
droplets, much less their encapsulation in polymer microspheres.  
Here, we report a process for the high-throughput encapsulation of cells in 




device with six parallel flow focusing nozzles. This microfluidic device is capable 
of efficiently encapsulating high concentration cell suspensions, and enables a 
600% increase in volumetric throughput rate over single nozzle configurations. 
Two different nozzle widths, 35 µm and 100 µm were developed, each with 
benefits and disadvantages. 35 µm wide nozzle devices produce smaller 
microgels than 100 µm wide nozzles and can uniformly break up droplets from 
precursors at higher operating cell densities as 100 µm-wide nozzle devices, 
which minimizes transplant graft volume. However, whereas hMSC viability is 
>90% after encapsulation on 100 µm wide nozzle devices , it is reduced to ~70% 
after encapsulation on 35 µm wide nozzle devices, and 100 µm wide nozzle 




5.3.1 Microfluidic fabrication 
Photolithography was used to pattern microfluidic masters after spin 
coating SU-8 2050 photoresist (MicroChem) onto silicon wafers, then 
masters were developed and treated with vapor phase 
trichloro(1H,1H,2H,2H-perfluorooctyl)silane (Sigma) to reduce sticking. 
Devices with 35 µm and 100 µm wide nozzles had focusing layer patterns 
that were 35µm and 100 µm tall, respectively, and their corresponding top 




mixed according to manufacturer specifications and was moulded on the 
SU-8 master to make microfluidic channel replicas (Figure 26A). After 
curing for 11 minutes at 110°C, crosslinker inlet and outlet holes were 
punched in the top layer, and inter-layer vias were punched in the bottom 
layer. Appropriate surfaces were exposed to air plasma for 20 seconds in a 
PlasmaPreen system, and layers were aligned and pressed together by 
hand before being cured at 110°C for 5 minutes. After PDMS to PDMS 
bond was stabilized, oil and macromer inlets were punched through both 
layers. These elastomer constructs were sonicated, along with glass 
substrates, in 200 proof ethanol and were dried with compressed nitrogen. 
Cleaned components were quickly treated with 12 seconds of plasma and 
PDMS was bonded to a glass slide, sealing the lower layer flow channels. 






Figure 26. Schematic and representative images demonstrating parallel 
microfluidic device operation and fabrication are shown. (A) Droplets containing 
macromer precursor (and optionally cells) are emulsified in oil on the lower layer 
of the device when these immiscible fluids are co-flowed through a flow focusing 
geometry. The droplets produced on all 6 flow focusing nozzles are carried up to 
the top layer where they are exposed to crosslinker and are pooled before exiting 
the device at a single outlet. (B) Fluorescent label facilitates visualization of 
microfluidic device operation, as seen in this photograph of microgel generation 
in progress. (C) The two layer microfluidic device requires several steps for 
fabrication. First, PDMS is moulded from SU-8 and silicon masters, then holes 
that go through one layer only are punched. PDMS layers are exposed to air 




punched through both layers, and the device is completed by bonding the two 
layer PDMS construct to a glass substrate after plasma exposure. 
5.3.2 Microgel synthesis and characterization  
Microfluidic devices were primed with Light Mineral Oil (Sigma) containing 
2% SPAN80 (Sigma) which was also used as the continuous phase fluid. 
The crosslinker emulsion was comprised of 30 mg/mL DTT (Sigma) 
emulsified at a 1:15 ratio in the continuous phase. The macromer solution 
consisted of 6.5% (w/v) PEG-4MAL (20 kDa, Laysan Bio), which had been 
reacted with a fluorescently labelled adhesive peptide (1.0 mM 
AlexaFluor594-conjugated GRGDSPC) for imaging and consistency with 
cell encapsulation experiments. Also motivated by consistency with 
subsequent cell encapsulation experiments, this reaction was performed in 
a buffer which had additives to address particular challenges associated 
with cell encapsulation. The buffer contained OptiPrep density gradient 
(Sigma) and PBS in a 1:4 ratio to match the density of cells and minimize 
settling of cells, and contained 0.1% Pluronic F108, which reduces cell 
sticking to glass or PDMS. After connecting the outlet and all inlets, fluid 
flows were driven at the flow rates prescribed in Table 1 by Hamilton 
gastight syringes on Harvard Apparatus Elite syringe pumps. To prevent 
unwanted gelation of polymer precursor on chip and to minimize 
polydispersity due to transient flows, first oil, then crosslinker fluid flows 
were initiated and allowed to stabilize. Only after flows stabilized was 




microgels were collected in phosphate buffered saline containing 2% 
bovine serum albumin (to reduce microgel sticking). Most of the oil was 
removed by aspiration after centrifugation (600g for 5 min), then microgels 
were washed 3 more times by centrifugation in a new 15 mL conical tube 
to remove any mineral oil residue from microgels. Microgels were imaged 
using a  Nikon Ti-E microscope with Perfect Focus System and C2-
Plus Confocal System, and diameter was determined using ‘Analyze 
Particles’ on binarized images in ImageJ. Output of 3 independent microgel 
generations were characterized for all 4 device designs tested, with a 
minimum of 163 microgels counted per device.  
 
 
Table 1. Microfluidic devices with parallel nozzle configuration have 600% 
increased macromer throughput rate over single nozzle configurations. Flow 






5.3.3 Human MSC microencapsulation and characterization 
A similar protocol was used to encapsulate hMSCs, with a few 
modifications. First, hMSCs were trypsinized for 10 minutes in 0.25% 
trypsin/EDTA, which minimized cell clumping and homogenized cell 
morphology compared to shorter trypsinization times. A macromer solution 
was made containing twice the desired final concentrations – that is 13 
wt% PEG-4MAL, 2.0 mM RGD, 0.2% Pluronic F108, in a buffer comprised 
of 1:2 OptiPrep in PBS. This precursor was mixed with an equal volume of 
cells suspended at twice their desired concentration. The resulting solution 
contained gel precursor concentrations consistent with those used for 
microgel synthesis, and contained the desired concentration of cells in 
suspension (2 x 107 cells/mL for 35 µm wide nozzle or 107 cells/mL for 100 
µm wide nozzle). This suspension was mixed thoroughly by pipetting, and 
was used as quickly as possible to generate microgels in parallel nozzle 
microfluidic devices, using the same protocol described for empty 
microgels. Three independent encapsulations were performed on both the 
35 µm and 100 µm wide nozzles for at least 20 minutes each, and the 
resulting microgels were washed with culture media 4 times by 
centrifugation. Live and dead cells were then stained with Calcein-AM and 
TOTO-3 iodide, respectively (ThermoFisher). Microgels containing cells 
were imaged on a confocal microscope and were measured in ImageJ. 




to cell clustering. At least 425 capsules were characterized from each 
encapsulation.  
5.3.4 Human MSC viability 
Viability of microencapsulated hMSC was monitored over time for cells 
encapsulated on parallel microfluidic devices with both 35 µm and 100 µm 
wide nozzles. Cell viability on day 0 was calculated by dividing the number 
of Calcein-AM positive cells by the total number of cells counted. Some 
encapsulated cells were not stained on day 0, and were instead cultured 
with media changes every 3 days. On days 1, 3, and 7 post-encapsulation, 
encapsulated cells were removed from culture, and were stained and 
imaged to determine cell viability. As a control, viability was also 
determined over time for hMSCs grown on TC plastic. Day 0 viability of 
cells in microgels was compared for cells encapsulated on 35 µm vs 100 
µm wide nozzle devices using Mann-Whitney test in GraphPad.  
 
5.4 Results and Discussion 
 
5.4.1 Microfluidic design and fabrication 
The goals of our iterative design were to (1) maximize throughput of encapsulated cells 
while (2) minimizing microgel size and maintaining encapsulated cell health and function. 
During the course of preliminary experiments with devices comprised of single square 
nozzles, nozzle widths smaller than 30 µm did not consistently encapsulate cells, 
especially hMSCs, which are relatively large cells with heterogeneous morphology. 




cells mixed with empty microgels. Therefore, 35 µm wide nozzles were determined to be 
the smallest nozzle appropriate for high throughput encapsulation of hMSCs. Also during 
these preliminary experiments, we observed that cell viability was reduced in these very 
small microgels, which might limit their therapeutic potential. Cells encapsulated on 100 
µm wide nozzles had higher viability, and therefore therapeutic potential, but they were 
still small enough that throughput limitations were a concern.  
Therefore, several different two layer parallel nozzle flow focusing microfluidic devices 
were designed and fabricated (for both 35 µm and 100 µm widths) using soft lithography, 
in an iterative design process. Initial designs had flow focusers on the top layer, which 
worked for the 100 µm wide nozzle, but the higher pressure required for driving flow on 
the 35 µm wide focusing nozzles caused frequent device failure due to delamination of 
the PDMS to PDMS bond. Delamination was entirely eliminated by relocating oil and 
macromer supply and flow focusers to the bottom layer, with its stronger glass to PDMS 
bond. On the final design (Figure 1), all flow channels on the top layer are relatively large 
and open (80 µm tall for devices with 35 µm wide nozzles; 140 µm tall for devices with 
100 µm wide nozzles), so they did not require pressures that instigated delamination. 
Devices which had more nozzles were also designed, but were more difficult to 
fabricate, and produced droplets with increased polydispersity. The 6 nozzle design 
represents a compromise, resulting in acceptable polydispersity as well as acceptable 







5.4.2 Parallel encapsulation allows for 600% increased throughput while 
maintaining size control of microgels 
. A major benefit of synthesizing microgels with droplet microfluidics is the ability 
to precisely control microgel size and polydispersity. However, maintaining low 
polydispersity is challenging in parallel nozzle devices, because any variation in 
fluidic resistance between flow focusers (or respective distribution/collection 
channels) results in variation of droplet size produced at each nozzle. 
Additionally, pressure fluctuations tend to propagate through all the nozzles, 
producing droplets with heterogeneous diameters. Therefore, we synthesized 
PEG-4MAL microgels on both single and parallel nozzle devices in order to 
characterize any increase in polydispersity due to parallel synthesis (Figure 27). 
Three separate syntheses were performed on three separate devices of each 
design. Representative histograms of microgel size are shown for each synthesis 
(Figure 27A,B) along with representative fluorescent images of microgels. 
Although Kruskal-Wallis tests indicate differences in median microgel size across 
devices of the same design (p<0.05 for all 4 devices), this is likely due to the 
small variances and large sample sizes. No gross differences in size distribution 
were seen between microgels generated on multiple devices of the same design 
(Figure 27) and mean microgel size was highly consistent between devices of the 
same design (Table 2). For practical purposes, we conclude that microgel 
production is repeatable on all 4 microfluidic designs. Microgels analysed from all 
3 encapsulations were pooled for each device so that comparisons could be 




µm wide nozzle device, a t-test revealed statistical differences (p=0.012, Figure 
27C) in mean diameter of microgels produced on parallel vs. single nozzles, but 
the magnitude of this difference was small (<1.8%) - average diameter was 65.1 
± 8.2 µm for parallel nozzle devices versus 64.0 ± 6.3 µm for single nozzle 
devices (Table 2). The mean diameter was equivalent for pooled microgels 
produced on 100 µm nozzles (104.5 µm), whether single or parallel 
configurations were used, and no differences in mean diameter were found 
(p=0.97). F-tests revealed differences in variance of microgel diameter for 
parallel vs. single nozzle production for both nozzle widths tested (p<0.0001 in 
each case). For 35 µm nozzle width, the parallel configuration resulted in higher 
standard deviations than the single configuration, as expected. Surprisingly, the 
single 100µm nozzle produced microgel diameters with higher standard 
deviations (± 9.6µm) than those produced on the parallel configuration (± 7.5µm). 
Whereas statistically significant differences were found between diameters of 
microgels produced on single versus parallel nozzle configurations, the 
differences are small and are unlikely to matter for practical applications. Taken 
together, these results demonstrate that our parallel microfluidic device is 
capable of increasing microgel production rate by 600%, while having minimal 









Table 2. Statistics for microgel populations produced on different microfluidic 
devices, with or without cells. Results are shown for three independent syntheses 
for each process. Measured values from all 3 syntheses are pooled in the right 







Figure 27. Microfluidic devices with parallel nozzles can produce microgels with 
controlled size, and with polydispersities comparable to microgels produced on a 
single nozzle. (A,B) Representative histograms of microgel diameter frequency 




single and parallel nozzles for both nozzle widths tested. (C) Consistency in 
diameter distribution is further demonstrated by comparing pooled microgels 
produced from each device. Significant differences were found between parallel 
and single configurations of 35µm nozzles (p=.0012) , but the magnitude of 
differences was not practically relevant. 100µm nozzles did not produce different 
sized microgels with parallel vs. single configurations (p=0.97). 
 
 
5.4.3 Human MSCs can be encapsulated on parallel nozzle microfluidic device 
with high loading density. 
The design criteria of maximum cell throughput and the desire for reduced 
transplant graft volume and microgel size both motivate a minimization of empty 
microgels and maximization of cell loading in each microgel. Increasing the cell 
concentration in macromer solution exacerbates several challenges that may 
prevent successful encapsulation. High concentration of hMSCs tend to 
aggregate in solution, which often results in many empty microgels and a 
relatively few, large microgels that contain clusters of cells. The tendency of 
hMSCs to aggregate was be reduced by increasing trypsin exposure from 5 
minutes to 10 minutes while harvesting cells, without notable deleterious effects 
on cell viability. Cells, especially when aggregating, tended to stick in microfluidic 
channels, forming sieves that prevent successful encapsulation. The addition of 





Cells also tended to settle in microfluidic tubing because their density is higher 
than a 6.5% PEG-4MAL solution in PBS, which results in increased cell 
aggregation and many empty microgels. After adding the cytocompatible density 
gradient media OptiPrep at a 1:4 ratio in cell suspensions, encapsulations up to 
30 minutes were completed without noticeable cell settling. These three process 
improvements enabled microencapsulation of hMSCs with relatively high loading 
densities, as shown by fluorescent images in  
Figure 28A. In these images, green indicates live cells (stained with Calcein-AM), 
red indicates dead cells (stained with TOTO-3 iodide), and blue indicates the 
outline of microgels (obtained using ‘Find Edges’ in ImageJ).   In our hands, 
maximum cell concentrations for robust encapsulation were determined to be 
2x107 cells/mL for 35 µm wide nozzle devices and 107 cells/mL for 100 µm wide 
nozzle devices. Histograms showing the frequency of capsules containing a 
given number of cells are shown in  
Figure 28B, along with the frequencies predicted by the Poisson distribution, 
using the measured average value as used as expected value. Measured 
frequencies for number of cells per microgel closely matched those predicted by 
the Poisson distribution for microencapsulation on both 35 µm and 100 µm wide 
nozzles, except that approximately two times more empty microgels are 
produced than expected on 35 µm wide nozzles. Fewer empty microgels are 





Figure 28C), which may lead to more uniform cell spacing in packed microgel 
arrays. 
The diameters of microgels which encapsulate hMSCs were measured 
from 3 separate parallel microfluidic devices for both 35 µm and 100 µm nozzle 
widths (Table 2). Cell-laden microgels produced on 100 µm wide nozzles had 
significantly smaller diameter than cell-free microgels, with a modest decrease in 
mean diameter of 6.4 µm, or 6.1%. Microgels produced on 35 µm wide nozzles 
were significantly larger when they contained cells than when no cells were 
present (p<0.0001), with an increase in mean diameter of 11.4 µm, or 18%. 
Whereas aggregation of cells could explain the larger size of capsules produced 
on 35 µm wide nozzles, increased polydispersity would be expected if this was 
the case. Surprisingly, the addition of cells decreased microgel polydispersity 
when compared to microgels with no cells, as seen by the lower coefficient of 
variation on 35 µm wide nozzles when cells were present. The presence of cells 
did not meaningfully impact polydispersity of microgels from 100 µm wide 
nozzles, although the F-test shows statistically significant differences in variance 










Figure 28. Parallel nozzle microfluidic devices can be used for high throughput 
encapsulation of hMSCs with high loading density, and resulting microgels 
support hMSC viability. (A) Representative images are shown for cells 




Microgels encapsulating hMSCs were functionalized with a fluorescently labelled 
peptide containing the cell adhesive sequence RGD in order to support cell 
health and aid microgel visualization (outline of microgels was traced in blue 
using ImageJ). Live cells were stained with Calcein-AM (green) and dead cells 
with TOTO-3 iodide (red). (B) The number of cells per microgel was recorded for 
3 independent encapsulations for each size nozzle, and their relative frequencies 
were plotted on histograms, along with the frequencies predicted by the Poisson 
distribution (grey bars). Number of cells in microgels produced on 100 µm wide 
nozzles closely matched the frequencies predicted by the Poisson distribution, 
but microgels produced on 35 µm wide nozzle devices contained more empty 
microgels than predicted. (C) Microencapsulation on 100 µm wide nozzles 
produces significantly fewer empty microgels than devices with 35 µm wide 
nozzles (p=0.02). (D) Addition of cells has significant effects on distributions of 
microgel diameter vs. cell-free microgels for both 35 µm width, where average 
microgel size increases, and 100 µm width, where average microgel size is 
decreases (p<0.0001 for both widths). (E) Viable cell fraction was determined 
over time in culture to measure the ability of microgels produced on each nozzle 
width to support hMSC health. Cells encapsulated on 100 µm wide nozzles had 
good viability on the day of encapsulation, and microgels reasonably supported 
their health for 7 days in culture. Cells encapsulated on 35 µm wide nozzles had 
significantly reduced viability on the day of encapsulation versus cells 




viability, cell viability decreased at similar rates to cells encapsulated on 100 µm 
wide nozzles. 
5.4.4 Microgels support hMSC viability, but the microencapsulation process 
reduces cell viability in a nozzle size-dependent fashion 
Human MSCs were encapsulated in microgels utilizing 3 separate devices in 
independent encapsulations, for both 35 µm and 100 µm nozzle widths with 
parallel configurations. These microgels were functionalized with a peptide that 
contained the cell adhesive sequence RGD to support adhesive signalling of 
encapsulated cells. On days 0, 1, 3, and 7 after encapsulation, live and dead 
cells were labelled with Calcein-AM and TOTO-3 iodide, respectively, before 
being imaged, and viable cell fractions were calculated as the fraction of live cells 
over the total number of cells counted for each sample (Figure 3E). Cells 
encapsulated on 100 µm wide nozzles had excellent initial viability of <90% on 
the day of encapsulation, and viability was remained high (<75%) on day 3 post-
encapsulation, indicating that microgels support cell health. In contrast, cells 
encapsulated on 35 µm wide nozzles average only 71% viability on the day of 
encapsulation, implicating the smaller dimensions of the device as damaging to 
cells. This damage could be due to increased probability of cells being exposed 
to membrane-disrupting mineral oil during encapsulation, which has been shown 
to decrease encapsulated cell viability [220]. After the initial loss of viability due to 
encapsulation, cells encapsulated on 35 µm wide nozzles died at about the same 
rate as cells encapsulated on 100 µm wide devices, showing that microgels of 





Synthetic hydrogels used to deliver cells in vivo can be engineered to provide 
important biochemical signals to encapsulated cells and host tissue, and 
tuneable pore size allows for immuno-isolation of encapsulated cells from host 
tissue. Bulk hydrogel constructs limit mass transport around encapsulated cells 
and are often prohibitively large when many cells are required. 
Microencapsulation, or the encapsulation of cells in microgels, can reduce mass 
transport limitations and large graft sizes associated with bulk encapsulation of 
cells, and enables injectable delivery of cells within controlled 
microenvironments. All of these benefits are enhanced as microgel diameter is 
decreased, but volumetric throughput decreases with the cube of nozzle width, 
so it can be difficult to encapsulate clinically relevant numbers of cells in very 
small microgels. The parallel microfluidic device presented here increases 
microgel throughput 6-fold with minimal change in polydispersity, for faster 
encapsulation of clinically relevant numbers of cells. Microencapsulation on 35 
µm wide nozzle devices can be done at very high cell loading (2*107 cells/mL), 
which results in relatively small microgels (76.5 ± 6.6 µm), minimizing graft 
volume and transport limitations. Unfortunately, encapsulation on 35 µm wide 
nozzle devices reduced cell viability to ~70%, and even on parallel nozzles, 
macromer throughput was only 1.2 µL/min – 12% of the 100 µm wide nozzle 
device throughput. In addition to higher throughput, microencapsulation of 
hMSCs on 100 µm wide nozzles resulted in excellent viability of <90%. The lower 




nozzles would result in increased graft volumes, but associated increases in cell 
viability and throughput may outweigh these concerns. Each nozzle width has 
been designed prioritizing differently the particular challenges associated with 
high throughput cell encapsulation in small microgels, but both of these devices 
utilize similar, novel approaches to solve limited cell throughput. By using high 
concentration cell suspensions and parallel flow focusing nozzles, clinically 
relevant cell numbers can be rapidly encapsulated in small microgels. 
This work was funded by NIH (R21EB020107) and the Juvenile Diabetes 


















Mitigating host rejection of transplanted cells without systemic 
immunosuppression is a major goal of transplant research, and new tools are 
needed to empower innovative intervention strategies. Biomaterials which 
microencapsulate therapeutic cells in perm-selective membranes have been 
utilized for passive immunoprotection. Specifically, pancreatic islets have been 
encapsulated in alginate-PLL microgels with tightly controlled permeability, and 
immune rejection of these islets was often reduced. Unlike alginate, some 
synthetic hydrogels can use click chemistry for facile functionalization with 
diverse bioactive molecules, including cell adhesive peptides for maintaining 
encapsulated cell function and immunomodulatory proteins for further mitigating 
host immune rejection. Unfortunately, the extrusion processing used for alginate 
microencapsulation is not suited to synthetic microgel production, so new 
strategies were needed to microencapsulate cells in synthetic hydrogels.  
 In aim 1, which was published in Advanced Materials [146], one such 
strategy was devised and characterized. A novel microfluidic device that was 
capable of cell and islet encapsulation in PEG-4MAL microgels was designed 
and fabricated. The relationship between flow rates and resulting microgel size 




4MAL microgels was characterized, revealing that diffusion of insulin and glucose 
is relatively unaffected, while diffusion of IgG antibodies is grossly limited. This 
suggests that PEG-4MAL microgels will act as effective immuno-isolation 
devices. Finally, human pancreatic islets and mesenchymal stem cells were 
encapsulated in PEG-4MAL microgels with no major reduction in viability or 
function, demonstrating the cyto-compatibility of the microencapsulation process. 
The approaches established in this aim were refined and applied for 
immunoprotection and immunomodulation of encapsulated islets in rodent 
models of T1D using two different strategies as presented in aims 2 and 3. In 
another refinement, novel two-layer microfluidic chips with parallel flow focusing 
geometry were used to microencapsulate immunomodulatory hMSCs with high 
throughput, as discussed in chapter 5. 
 In aim 2, islet microencapsulation in PEG-4MAL hydrogels was optimized, 
first in vitro and later in syngeneic diabetic recipients. First, bulk hydrogel 
encapsulation was used to determine the best available adhesive peptide 
sequence for supporting islet function and survey the effects of different 
crosslinkers on encapsulated islets. Islets encapsulated in RGD functionalized 
PEG-4MAL containing degradable crosslinks performed the best, but this 
material would not be suitable for long-term immunoisolation applications. 
Therefore, nondegradable DTT crosslinked hydrogels were preferred for their 
stability, since they supported adequate islet function, comparable to alginate. 




microfluidics had only slightly reduced viability compared to unencapsulated 
control islets, and their glucose responsiveness was not reduced or delayed 
measurably by microencapsulation. These same nondegradable PEG-4MAL 
microgels supported function of single-donor islet mass to the EFP of syngeneic 
diabetic recipients, when delivered within a vasculogenic bulk hydrogel. 
Restoration of glycemic control in with PEG-4MAL microencapsulated islets was 
similar to seen with unencapsulated control islets delivered to the EFP in 
vasculogenic bulk gels, since similar proportions of grafts restored euglycemia at 
similar rates in both groups, . In contrast, islets microencapsulated in larger, 
alginate microgels did not restore euglycemia when delivered to the EFP in 
vasculogenic bulk hydrogels (n=5). The relatively larger size of alginate microgels 
may provide a large enough diffusional barrier to reduce islet function, possibly 
inducing hypoxia. Even though PEG-4MAL microencapsulated islets were not 
directly connected with host circulation as was seen with unencapsulated islets, 
induced vasculature surrounded microgels, and therefore smaller microgels 
resulted in less distance between islets and host blood supply. Delivering 
alginate microencapsulated single donor islet mass IP results in rapid reduction 
in blood glucose, but gradual loss of islet function is seen by increasing 
fluctuations in daily blood glucose and eventually by graft failure in some cases. 
This decline in function could be explained by hypoxia due to poor proximity of 
islets to host circulation. In this aim, we successfully optimized a hydrogel 
delivery strategy which minimizes mass transport limitations associated with 




dense vascularization between microgels. This strategy was shown to be 
effective at maintaining islet function in syngeneic models, and is currently being 
tested for immuno-isolation potential in allogeneic murine models.  
 As shown by the results of aim 3, which is in preparation for publication, 
microgels presenting immunomodulatory SA-FasL conferred graft acceptance to 
co-transplanted islets in a murine model of T1D. Biotinylated microgels were 
produced by pre-reacting PEG-4MAL macromer with biotin-PEG-thiol, and these 
biotinylated microgels were shown to bind and display bioactive SA-FasL in a 
dose-dependent fashion. SA-FasL is an engineered immunomodulatory protein 
that has previously been captured on modified cells, resulting in graft acceptance 
without the need for long term immunosuppression. Likewise, SA-FasL modified 
microgels transplanted with allogeneic islets under the kidney capsule of diabetic 
mice resulted in long term (200 day) graft acceptance with only transient (14 day) 
administration of systemic immunosuppression. This graft acceptance was found 
to be correlated with an increase in the ratio of Treg:Teff cells in transplanted 
kidneys, demonstrating active immunomodulation due to SA-FasL presenting 
microgels. Notably, this immunoprivileged status was localized to the graft, and 
systemic immune response was not affected by SA-FasL presenting microgels. 
This approach demonstrates the efficacy of active immunomodulation, which is 
sufficient to confer graft tolerance, even when no physical barrier is placed 
between donor islets and host immune system. Because simple mixing of SA-




immune reaction, this approach is amenable to widespread clinical deployment 
as an off-the-shelf product. Because of the clinical significance of this strategy, 
along with promising preliminary results in rodents, efficacy of SA-FasL 
codelivery with allogeneic islets in diabetic nonhuman primates will be evaluated 
in upcoming studies. If these studies are successful, rapid transition to clinical 
trials should be undertaken as quickly as possible so that diabetic human 
patients can benefit. If immunoprotective deficiencies are found in nonhuman 
primate studies, the approach can be modified in two ways. First, other 
engineered immunomodulatory proteins chimeric with SA, such as SA-PD-L1, 
may be more effective at conferring graft acceptance than SA-FasL due to 
increased immunomodulatory efficacy. Therefore, identification, production, and 
testing of these immunomodulatory proteins should be a priority. Second, rather 
than mixing SA-FasL microgels with unmodified islets, islets could be 
microencapsulated in biotinylated microgels onto which SA-FasL is captured 
before transplantation. Microencapsulation adds the immunoprotective benefits 
of permselectivity but would complicate the clinical deployment of resulting 
interventions. 
Chapter 5 presents the design and optimization of a novel two-layer 
microfluidic device with parallel flow focusing nozzles for high throughput cell 
encapsulation. This parallel configuration increases the throughput of microgels 
by 600% without major increases in polydispersity for devices with 35µm or 




synthetic microgels under 100µm diameter with uniform size and can be 
operated with high cell loading density to reduce graft volume and facilitate 
injection of encapsulated cells. 100µm nozzle microencapsulation results in 90% 
post-encapsulation viability with hMSCs, and has very high macromer volumetric 
throughput of 10µL/min. 35µm nozzle microencapsulation results in reduced 
post-encapsulation viability of 71% with hMSCs and utilizes a reduced macromer 
volumetric throughput of 1.2µL/min, but the smaller nozzles can make uniform 
droplets with cell suspensions twice as dense as those used for 100µm nozzle 
microencapsulation and smaller nozzles produce smaller microgels which may 
be advantageous for some applications. This technology was developed to 
encapsulate clinically relevant numbers of MSCs very small microgels which 
were to be infused into coronary circulation where they would lodge and secrete 
angiogenic and other pro-healing factors. Dosing studies were performed in pigs 
to determine how many microgels produced on 35µm nozzles could be infused 
without reduction in cardiac function (data not shown). However, post-
encapsulation viability was poor for these MSCs, so therapeutic efficacy of this 
approach is doubtful with current encapsulation methods. It is likely that cell 
viability in microgels produced on 35µm nozzles is reduced due to exposure to 
membrane-disrupting mineral oil when droplets are being produced. Therefore, 
one approach to increase viability of microencapsulated cells is to use a cyto-
compatible continuous phase, such as a perfluorinated hydrocarbon continuous 
phase, stabilized with fluorinated surfactants with non-ionic head groups. This 




mechanism of crosslinking is required. Photocrosslinkable norbornene-
functionalized 4-arm PEG macromers may enable use of cyto-compatible 
continuous phases without drastic changes to microgel properties. Although 
viability concerns preclude the use of cells encapsulated on 35µm nozzles with 
mineral oil for therapeutic applications, microgels containing cells encapsulated 
on 100µm nozzles are only around 30% larger in diameter than those produced 
on 35µm nozzles and have good post-encapsulation viability. These cell-laden 
microgels, which can act as engineered stem cell niches when appropriate cell-
instructive cues included, can be injected in minimally invasive transplant 
procedures. The applications of this technology - including injectable delivery of 
MSCs for immunomodulation and healing, and mixing of microgels with various 
payloads in a ‘bottom up’ approach – are numerous, and this powerful tool 
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